Method for eliciting unconventional t cells using species-mismatched cytomegalovirus
Recombinant cytomegalovirus vectors expressing human TRS1 and IRS1 with specific mutations induce MHC-E and MHC-II restricted CD8+ T cells, overcoming species barriers and improving immune responses against pathogens and cancers.
Patent Information
- Application Number
- PCT/US2026/026562
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-04
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cytomegalovirus-based vaccines fail to elicit unconventional MHC-restricted CD8+ T cell responses across species, limiting their effectiveness in providing broad protection against pathogens and cancers.
Development of recombinant cytomegalovirus vectors that express active TRS1 and/or IRS1 from human cytomegalovirus and lack active Rh230 or Cy230, along with specific mutations in ULI genes, to induce MHC-E and MHC-II restricted CD8+ T cell responses in non-human primates, using vectors like RhCMV and CyCMV.
The recombinant vectors effectively elicit a significant proportion of CD8+ T cells restricted by MHC-E or MHC-II, enhancing immune responses against pathogens and tumors, and enabling targeted treatment and prevention strategies.
Smart Images

Figure IMGF000023_0001_TABLE 
Figure IMGF000024_0001_TABLE 
Figure IMGF000027_0001_TABLE
Abstract
Description
METHOD FOR ELICITING UNCONVENTIONAL T CELLS USING SPECIES- MISMATCHED CYTOMEGALOVIRUSSTATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH AND DEVELOPMENT
[0001] This disclosure was created with the support of the United States government under the terms of grant numbers P01 AI174856, awarded by the National Institute of Allergy and Infectious Disease. The U.S. Government has certain rights in this invention.CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] The present application claims the priority benefit of U.S. Provisional Application No. 63 / 799,619, filed May 4, 2025, which is hereby incorporated by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0003] The content of the electronically submitted sequence listing in XML text file (Name 4153_016PC01_SequenceListing_ST26.xml; Size: 29,433 bytes; and Date of Creation: April 29, 2026) filed with the application is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION
[0004] Infection of rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) elicits classical MHC -la-restricted CD8+ T cell responses whereas inoculation with RhCMV deleted for orthologs of HCMV chemokine-like genes ULI 28, ULI 30 and ULI 46 induces exclusively MHC-II and MHC-E restricted CD8+ T cells. MHC-E restricted T cells are required for RhCMV-based SIV vaccines to provide a unique “control and clear” protection against highly virulent SIVmac239. Vaccination of Mauritian-origin cynomolgus macaques (MCM) with similarly genetically modified cynomolgus (Cy)CMV / SIV vectors elicited MHC-E and MHC-II restricted CD 8+ T cells and protected against SIVmac239 challenge. In contrast, immunization of RM with CyCMVor MCM with RhCMV failed to elicit unconventionally MHC-restricted T cells suggesting species-specific factors needed for T cell re-programming.BRIEF SUMMARY OF THE INVENTION
[0005] Disclosed herein are recombinant rhesus cytomegalovirus (RhCMV) vectors comprising a nucleic acid sequence encoding one or more heterologous antigens, wherein the RhCMV vector expresses an active TRS1 and / or an active IRS1 and does not express an active Rh230. In some aspects, the active TRS1 and / or active IRS1 are from human cytomegalovirus (HCMV).
[0006] In some aspects, the recombinant RhCMV vector does not express active Rh230 due to the presence of one or more mutations in the nucleic acid sequence encoding Rh230. In some aspects, the one or more mutations in the nucleic acid sequence encoding Rh230, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the Rh230.
[0007] Also disclosed herein are recombinant cynomolgus cytomegalovirus (CyCMV) vectors comprising a nucleic acid sequence encoding one or more heterologous antigens, wherein the CyCMV vector expresses an active TRS1 and / or an active IRS1 and does not express an active Cy230. In some aspects, the active TRS1 and / or active IRS1 are from HCMV.
[0008] In some aspects, the recombinant CyCMV vector does not express active Cy230 due to the presence of one or more mutations in the nucleic acid sequence encoding Cy230. In some aspects, the one or more mutations in the nucleic acid sequence encoding Cy230, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the Cy230.
[0009] In some aspects, the recombinant non-human primate cytomegalovirus vector does not express an active ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof. In some aspects, the recombinant vector does not express active ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof, due to the presence of one or more mutations in the nucleic acid sequence encoding ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof. In some aspects, the one or more mutations in the nucleic acid sequence encoding ULI 28, UL130, UL146, UL147, or an ortholog thereof, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of thenucleic acid sequence encoding the U I 28, U I 30, ULI 46, ULI 47, or an ortholog thereof.
[0010] In some aspects, the recombinant non-human primate cytomegalovirus vector further comprises a nucleic acid sequence encoding UL40, or an ortholog thereof. In some aspects, the recombinant vector further comprises a nucleic acid sequence encoding US28, or an ortholog thereof. In some aspects, the recombinant vector does not express active UL82 (pp71), or an ortholog thereof. In some aspects, the recombinant vector does not express active glycoprotein L (gL), or an ortholog thereof.
[0011] In some aspects, the recombinant non-human primate cytomegalovirus vector further comprises a nucleic acid sequence encoding a microRNA (miRNA) recognition element (MRE), wherein the MRE contains target sites for microRNAs expressed in endothelial cells. In some aspects, the MRE is specific for the miRNA selected from the group consisting of miR126, miR-126-3p, miR-130a, miR-210, miR-221 / 222, miR-378, miR-296, and miR-328.
[0012] In some aspects, the heterologous antigen is a pathogen specific antigen, a tumor antigen, a tissue specific antigen, or a host self-antigen. In some aspects, the pathogen specific antigen is selected from the group consisting of human immunodeficiency virus (HIV), herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
[0013] In some aspects, the pathogen specific antigen is an MHC-E supertope. In some aspects, the MHC-E supertope is a HIV epitope. In some aspects, the MHC-E supertope has a sequence having at least 80%, at least 85%, at least 90%, at least 95%, or is 100% identical to any one of SEQ ID NOs: 5-24.
[0014] In some aspects, the tumor antigen is related to a cancer selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
[0015] In some aspects, the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.
[0016] Also disclosed herein are methods of generating an immune response in a subject to the one or more heterologous antigens, comprising administering to the subject the recombinant vector in an amount effective to elicit a CD8+ T cell response to the one or more one heterologous antigens.
[0017] Also disclosed herein are methods of treating or preventing cancer in a subject, comprising administering the recombinant vector in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
[0018] Also disclosed herein are methods of treating or preventing a pathogenic infection in a subject, comprising administering to the subject the recombinant vector in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
[0019] Also disclosed herein are methods of treating an autoimmune disease or disorder in a subject, comprising administering to the subject the recombinant vector in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
[0020] In some aspects, at least 10% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-E or an ortholog thereof. In some aspects, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-E or an ortholog thereof.
[0021] In some aspects, at least 10% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-II or an ortholog thereof. In some aspects, at least 20%, at least 30%, at least 40%, at least 50%, at least 60% or at least 75% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-II or an ortholog thereof.
[0022] In some aspects, fewer than 10%, fewer than 20%, fewer than 30%, fewer than 40%, or fewer than 50% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-class la or an ortholog thereof. In some aspects, at least 10% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-class la or an ortholog thereof. In some aspects, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or the CD8+ T cells elicited by the recombinant vector are restricted by MHC-class la or an ortholog thereof.
[0023] In some aspects, the method comprises identifying a CD8+ TCR from the CD8+ T cells elicited by the recombinant vector, wherein the CD8+ TCR recognizes a MHC- n / heterologous antigen-derived peptide complex.
[0024] In some aspects, the method comprises identifying a CD8+ TCR from the CD8+ T cells elicited by the recombinant vector, wherein the CD8+ TCR recognizes a MHC- E / heterologous antigen-derived peptide complex.
[0025] In some aspects, the method comprises identifying a CD8+ TCR from the CD8+ T cells elicited by the recombinant vector, wherein the CD8+ TCR recognizes a MHC- la / heterologous antigen-derived peptide complex.
[0026] In some aspects, the CD8+ TCR is identified by DNA or RNA sequencing. In some aspects, the CD8+ TCR recognizes MHC-II supertopes. In some aspects, the CD8+ TCR recognizes MHC-E supertopes. In some aspects, the MHC-E supertope is an human immunodeficiency virus (HIV) epitope. In some aspects, the MHC-E supertope has an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the sequence of any one of SEQ ID NOs: 5-24.
[0027] Also disclosed herein are methods of generating TCR-transgenic CD8+ T cells that recognize MHC-E-peptide complexes, the method comprising: a) administering to a first subject the recombinant vector in an amount effective to generate a set of CD8+ T cells that recognize MHC-E / peptide complexes; b) identifying a first CD8+ TCR from the set of CD8+ T cells, wherein the first CD8+ TCR recognizes a MHC-E / heterologous antigen-derived peptide complex; c) isolating one or more CD8+ T cells from a second subject; and d) transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ TCR and a promoter operably linked to the nucleic acid sequence encoding the second CD8+ TCR, wherein the second CD8+ TCR comprises CDR3a and CDR3P of the first CD8+ TCR, thereby generating one or more transfected CD8+ T cells that recognize a MHC-E / heterologous antigen-derived peptide complex.
[0028] In some aspects, the first CD8+ T cell recognizes MHC-E supertopes. In some aspects, the MHC-E supertopes comprise human immunodeficiency virus epitopes. In some aspects, the MHC-E supertope has an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or is 100% identical to the sequence of any one of SEQ ID NOs: 5-24.
[0029] In some aspects, the second CD8+ T cell recognizes MHC-E supertopes. In some aspects, the MHC-E supertopes comprise human immunodeficiency virus epitopes. In some aspects, the MHC-E supertope has an amino acid sequence at least 80%, at least85%, at least 90%, at least 95%, or is 100% identical to the sequence of any one of SEQ IDNOs: 5-24.
[0030] In some aspects, the first CD8+ TCR is identified by DNA or RNA sequencing.
[0031] In some aspects, the nucleic acid sequence encoding the second CD8+ TCR is identical to the nucleic acid sequence encoding the first CD8+ TCR.
[0032] In some aspects, the first subject is a human. In some aspects, the second subject is a human.
[0033] In some aspects, the method further comprises administering the transfected CD8+ T cells to the second subject to treat or prevent cancer. In some aspects, the cancer is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
[0034] In some aspects, the method further comprises administering the transfected CD8+ T cells to the second subject to treat or prevent a pathogenic infection. In some aspects, the pathogenic infection is caused by a pathogen selected from the group consisting of human immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
[0035] In some aspects, the method further comprises administering the transfected CD8+ T cells to the subject to induce an autoimmune response to the host self-antigen.
[0036] Also disclosed herein are methods of generating CD8+ T cells that recognize MHC-E-peptide complexes, the method comprising: a) administering to a first subject the recombinant vector in an amount effective to generate a set of CD8+ T cells that recognize MHC-E / peptide complexes; b) identifying a first CD8+ TCR from the set of CD8+ T cells, wherein the first CD8+ TCR recognizes a MHC-E / heterologous antigen- derived peptide complex; c) isolating one or more CD8+ T cells from a second subject; and d) transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ TCR and a promoter operably linked to the nucleic acid sequence encoding the second CD8+ TCR, wherein the second CD8+ TCR comprises CDR3a and CDR3P of the first CD8+ TCR,thereby generating one or more transfected CD8+ T cells that recognize a MHC- E / heterologous antigen-derived peptide complex.
[0037] In some aspects, the first CD8+ T cell recognizes MHC-E supertopes. In some aspects, the second CD8+ T cell recognizes MHC-E supertopes. In some aspects, the first CD8+ TCR is identified by DNA or RNA sequencing.
[0038] In some aspects, the nucleic acid sequence encoding the second CD8+ TCR is identical to the nucleic acid sequence encoding the first CD8+ TCR.
[0039] In some aspects, the first subject is a human. In some aspects, the second subject is a human.
[0040] In some aspects, administering the recombinant vector to the first subject comprises intravenous, intramuscular, intraperitoneal, or oral administration of the recombinant vector to the first subject.
[0041] In some aspects, the method further comprises administering the transfected CD8+ T cells to the second subject to treat or prevent cancer.
[0042] In some aspects, the cancer is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
[0043] In some aspects, the method further comprises administering the transfected CD8+ T cells to the second subject to treat or prevent a pathogenic infection.
[0044] In some aspects, the pathogenic infection is caused by a pathogen selected from the group consisting of human immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
[0045] In some aspects, the method further comprises administering the transfected CD8+ T cells to the subject to induce an autoimmune response to the host self-antigen.
[0046] Also disclosed herein are CD8+ T cells generated by the methods.
[0047] In some aspects, the pathogen specific antigen is selected from the group consisting of human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
[0048] In some aspects, the tumor antigen is related to a cancer selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
[0049] In some aspects, the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.
[0050] Also disclosed herein are methods of treating or preventing a pathogenic infection in a subject, the method comprising administering the CD8+ T to the subject.
[0051] Also disclosed herein are methods of treating or preventing cancer in a subject, the method comprising administering the CD8+ T to the subject.
[0052] Also disclosed herein are methods of treating an autoimmune disease or disorder, the method comprising administering the CD8+ T cell to the subject.
[0053] Also disclosed herein are methods of inducing an autoimmune response to a host self-antigen, the method comprising administering the CD8+ T cell to the subject.BRIEF DESCRIPTION OF THE DRAWINGS / FIGURES
[0054] FIGs. 1A-1B is a schematic illustrating the generation of chimeric RhCMV / CyCMV vectors using transformation-associated recombination (TAR) cloning of CMV genomes. FIG. 1A is a schematic illustrating the use of TAR cloning to generate recombinant cytomegaloviruses in yeast. FIG. IB is a schematic showing the 16 overlapping DNA fragments captured from double-deleted (deleted for Rhl57.4, Rhl57.5, and Rhl58-161, or Cyl57.4, Cyl57.5, and Cyl58-161; orthologs of UL128, ULI 30, ULI 46, and ULI 47) RhCMV and CyCMV genomes (top). The fragments were assembled into overlapping quarter genomes (middle). Chimeric vectors containing three quarter RhCMV genomes and one quarter CyCMV genomes were assembled via homologous recombination (bottom). All vectors contained FL-RhCMV derived direct terminal repeats to allow for genome circulation and rolling circle genome replication. Chimeric recombinants were confirmed by next-generation sequencing and reconstitutedin primary rhesus fibroblasts. R represents a segment from the RhCMV genome and C represents a segment from the CyCMV genome.
[0055] FIG. 2 are scatter plots showing the results of flow cytometric intracellular cytokine staining (ICS) for TNF-alpha (y-axis) and INF-gamma (x-axis) of CD8+ T cells from rhesus macaques (RMs) immunized with the indicated recombinant RhCMV vectors (generated as in FIG. 1). Each of the four chimeric vectors expressed SIV Gag. T cell assays were conducted in the presence of 15mer peptides overlapping by 11 amino-acids and representing the entire Gag open reading frame (ORF), the 15mer peptides Gag 53 and Gag 73 representing supertopes presented by MHC-II, or the 15mer peptides Gag 69 and Gag 120 representing supertopes presented by MHC-E. Note that the RRRC vector carrying the 3 ’-terminal quarter genome of CyCMV failed to elicit MHC-II or MHC-E supertope-restricted CD8+ T cell responses.
[0056] FIG. 3 shows the MHC -restriction of individual peptides in individual rhesus macaques immunized with the indicated recombinant RhCMV vectors. MHC restriction of CD8+ T cell responses were determined by performing the ICS assay with individual 15mer peptides covering the indicated region of SIV Pol (the 65th15mer to the 90th15mer) or SIV Gag (the 45th15mer to the 75th15mer). T cell responses were either performed in the presence of control antibody, W6 / 32 antibody (anti-MHC-I), anti-MHC- II antibody (MHC-II blocking), or VL9 peptide (MHC-E blocking). Any peptide response that was not fully blocked by any of these reagents is marked indeterminate. Boxes depict Pol or Gag 15mers recognized by CD8+ T cells in a given animal with symbols indicating MHC-restriction of each response as indicated in the legend. Note that CRRR, RCRR, RRCR elicited CD8+ T cell responses that were restricted by MHC-II and MHC-E whereas RRRC elicited CD8+ T cell responses elicited by MHC-Ia.
[0057] FIG. 4 are scatter plots showing the results of flow cytometric ICS for TNF-alpha (y-axis) and INF-gamma (x-axis) of CD8+ T cells from a Mauritian-origin cynomolgus macaques (MCM) immunized with the recombinant RhCMV vectors RRRC (generated as in FIG. 1) expressing SIV Gag. Results of CD8+ T cell responses to RhCMV lysate, a pool of overlapping Gag peptides, or supertope peptides representative for MHC-II or MHC-E restriction (as in Fig. 2) are shown. In contrast to RM shown in Fig. 2, the recombinant RRRC elicited T cells to representative MHC-II and MHC-E supertopes in MCM.
[0058] FIG. 5 shows the frequencies of CD4+ or CD8+ T cell responses over time determined by ICS for TNFa and / or IFNg to overlapping SIV Gag peptides (left panels), or the CD8+ T cell responses to the MHC-E restricted supertopes Gag 69 and Gag 120 (middle panels), or to the MHC-II restricted supertopes Gag 53 or Gag 73 (right panels). The top row represents the results from a RM inoculated with a recombinant, doubledeleted (dd) RhCMV with the following genetic modifications: Rhl3.1 was replaced with SIV Gag, the UL128 and UL130 orthologs Rhl57.4 and Rhl57.5 were deleted, the Rhl58-Rhl61 gene region encoding the ULI 46 and ULI 47 orthologs was deleted, and the Rh230 gene encoding the TRS1 ortholog was replaced with Cy230 from CyCMV. The bottom row represents the results from a RM inoculated with a recombinant doubledeleted (dd) CyCMV with the following genetic modifications: Cyl3.1 was replaced with SIV Gag, the UL128 and UL130 orthologs Cyl57.4 and Cyl57.5 were deleted, the Cyl58-Rhl61 gene region encoding the ULI 46 and ULI 47 orthologs was deleted, and the Cy230 gene encoding the TRS1 ortholog was replaced with Rh230 from RhCMV.
[0059] FIG. 6 shows the frequencies of CD4+ or CD8+ T cell responses over time determined by ICS for TNFa and / or IFNg to overlapping SIV Gag peptides (left panels), or the CD8+ T cell responses to the MHC-E restricted supertopes Gag 69 and Gag 120 (middle panels), or to the MHC-II restricted supertopes Gag 53 or Gag 73 (right panels). The top row represents the results from a MCM inoculated with a recombinant dd- RhCMV with the following genetic modifications: Rhl3.1 was replaced with SIV Gag, the UL128 and UL130 orthologs Rhl57.4 and Rhl57.5 were deleted, the Rhl58-Rhl61 gene region encoding the ULI 46 and ULI 47 orthologs was deleted, and the Rh230 gene encoding the TRS1 ortholog was replaced with Cy230 from CyCMV. The bottom row represents the results from a RM inoculated with a recombinant dd-CyCMV with the following genetic modifications: Cyl3.1 was replaced with SIV Gag, the UL128 and UL130 orthologs Cyl57.4 and Rhl57.5 were deleted, the Cyl58-Rhl61 gene region encoding the ULI 46 and ULI 47 orthologs was deleted, and the Cy230 gene encoding the TRS1 ortholog was replaced with Rh230 from RhCMV.
[0060] FIG. 7 is an alignment of the predicted protein sequences of RhCMV gene Rh230 (Genbank Accession number: YP_068317.1) and CyCMV gene Cy230 (Genbank Accession Number: WAQ80560.1). Alignments were generated with the Clustal Omega Program on the UniProt server.
[0061] FIG. 8 is an alignment of the predicted protein sequences of HCMV gene TRS1 (Genbank Accession number: QHB20457.1) and HCMV gene IRS1 (Genbank Accession Number: QHB20447.1) both from HCMV clone TR3. Alignments were generated with the Clustal Omega Program on the UniProt server.
[0062] FIG. 9 is an alignment of the predicted protein sequences of RhCMV gene Rh230 (Genbank Accession number: YP 068317.1) and HCMV gene TRS1 (Genbank Accession Number: QHB20457.1). Alignments were generated with the Clustal Omega Program on the UniProt server.DETAILED DESCRIPTION OF THE INVENTIONI. Terms
[0063] Unless otherwise noted, technical terms are used according to conventional usage.
[0064] All publications, patents, patent applications, internet sites, and accession numbers / database sequences (including both polynucleotide and polypeptide sequences) cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, internet site, or accession number / database sequence were specifically and individually indicated to be so incorporated by reference.
[0065] Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of this disclosure, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided.
[0066] Antigen: As used herein, the terms "antigen" or "immunogen" are used interchangeably to refer to a substance, typically a protein, which is capable of inducing an immune response in a subject. The term also refers to proteins that are immunologically active in the sense that once administered to a subject (either directly or by administering to the subject a nucleotide sequence or vector that encodes the protein) the protein is able to evoke an immune response of the humoral and / or cellular type directed against that protein.
[0067] Antigen-specific T cell: A CD8+or CD4+lymphocyte that recognizes a particular antigen. Generally, antigen-specific T cells specifically bind to a particular antigen presented by MHC molecules, but not other antigens presented by the same MHC.
[0068] Administration: As used herein, the term "administration" means to provide or give a subject an agent, such as a composition comprising an effective amount of a CMV vector comprising an exogenous antigen by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, sublingual, rectal, transdermal, intranasal, vaginal and inhalation routes.
[0069] Cercopithecidae: As used herein, the term " Cercopithecidae" refers to a family of primates from the superfamily Cercopithecoidea. The family of Cercopithecidae comprises 24 genera and 138 species. The term "member of the family Cercopithecidae" or "Cercopithecidae" refers to any of the 24 genera or 138 species of Cercopithecidae . The genera of the Cercopithecidae family include Genus Allenopithecus (Allen's swamp monkey), Genus Allochrocebus (terrestrial guenons), Genus Cercocebus (white-eyelid mangabeys), Genus Cercopithecus (guenons), Genus Chlorocebus (vervet monkeys), Genus Erythrocebus (patas monkeys), Genus Lophocebus (crested mangabeys), Genus Macaca (macaques), Genus Mandrillus (mandrills), Genus Miopithecus (talapoins), Genus Papio (baboons), Genus Rungwecebus (kipunji), Genus Theropithecus (gelada), Genus Allenopithecus (Allen's swamp monkey), Genus Allochrocebus (terrestrial guenons), Genus Cercocebus (white-eyelid mangabeys), Genus Cercopithecus (guenons), Genus Chlorocebus (vervet monkeys), Genus Erythrocebus (patas monkeys), Genus Lophocebus (crested mangabeys), Genus Macaca (macaques), Genus Mandrillus (mandrills), Genus Miopithecus (talapoins), Genus Papio (baboons), Genus Rungwecebus (kipunji), and Genus Theropithecus (gelada).
[0070] Effective amount: As used herein, the term "effective amount" refers to an amount of an agent, such as a CMV vector comprising a heterologous antigen or a transfected CD8+ T cell that recognizes a MHC-E / heterologous antigen-derived peptide complex, a MHC-II / heterologous antigen-derived peptide complex, or a MHC- I / heterologous antigen-derived peptide complex, that is sufficient to generate a desired response, such as reduce or eliminate a sign or symptom of a condition or disease or induce an immune response to an antigen. In some examples, an "effective amount" is one that treats (including prophylaxis) one or more symptoms and / or underlying causes ofany of a disorder or disease. An effective amount may be a therapeutically effective amount, including an amount that prevents one or more signs or symptoms of a particular disease or condition from developing, such as one or more signs or symptoms associated with infectious disease or cancer.
[0071] Heterologous antigen: As used herein, the term “heterologous antigen” refers to any protein or fragment thereof that is not derived from CMV. Heterologous antigens may be pathogen-specific antigens, tumor virus antigens, tumor antigens, host selfantigens, or any other antigen.
[0072] Human Cytomegalovirus: As used herein, the term "human cytomegalovirus," "HCMV," "human herpesvirus 5," or "HHV-5" refers to a double-stranded DNA betaherpesvirus within the Cytomegalovirus genus.
[0073] Hyperproliferative disease: A disease or disorder characterized by the uncontrolled proliferation of cells. Hyperproliferative diseases include, but are not limited to malignant and non-malignant tumors.
[0074] Immune tolerance: As used herein "immune tolerance" refers to a state of unresponsiveness of the immune system to substances that have the potential to induce an immune response. Self-tolerance to an individual's own antigens, for example, tumor antigens, is achieved through both central tolerance and peripheral tolerance mechanisms.
[0075] Immunogenic peptide: A peptide which comprises an allele-specific motif or other sequence, such as an N-terminal repeat, such that the peptide will bind an MHC molecule and induce a cytotoxic T lymphocyte ("CTL") response, or a B cell response (for example antibody production) against the antigen from which the immunogenic peptide is derived.
[0076] In one embodiment, immunogenic peptides are identified using sequence motifs or other methods, such as neural net or polynomial determinations known in the art. Typically, algorithms are used to determine the "binding threshold" of peptides to select those with scores that give them a high probability of binding at a certain affinity and will be immunogenic. The algorithms are based either on the effects on MHC binding of a particular amino acid at a particular position, the effects on antibody binding of a particular amino acid at a particular position, or the effects on binding of a particular substitution in a motif-containing peptide. Within the context of an immunogenic peptide, a "conserved residue" is one which appears in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. In oneembodiment, a conserved residue is one where the MHC structure may provide a contact point with the immunogenic peptide.
[0077] MicroRNA: As used herein, the term "microRNA" refers to a major class of biomolecules involved in control of gene expression. For example, in human heart, liver or brain, miRNAs play a role in tissue specification or cell lineage decisions in addition, miRNAs influence a variety of processes, including early development, cell proliferation and ceil death, and apoptosis and fat metabolism. The large number of miRNA genes, the diverse expression patterns, and the abundance of potential miRNA targets suggest that miRNAs may be a significant source of genetic diversity.
[0078] A mature miRNA is typically an 8-25 nucleotide non-coding RNA that regulates expression of an mRNA including sequences complementary to the miRNA. These small RNA molecules are known to control gene expression by regulating the stability and / or translation of mRNAs. For example, miRNAs bind to the 3' UTR of target mRNAs and suppress translation. MiRNAs may also bind to target mRNAs and mediate gene silencing through the RNAi pathway. MiRNAs may also regulate gene expression by causing chromatin condensation.
[0079] A miRNA silences translation of one or more specific mRNA molecules by binding to a miRNA recognition element (MRE,) which is defined as any sequence that directly base pairs with and interacts with the miRNA somewhere on the mRNA transcript. Often, the MRE is present in the 3' untranslated region (UTR) of the mRNA, but it may also be present in the coding sequence or in the 5' UTR. REs are not necessarily perfect complements to miRNAs, usually having only a few bases of complementarity to the miRNA and often containing one or more mismatches within those bases of complementarity. The MRE may be any sequence capable of being bound by a miRNA sufficiently that the translation of a gene to which the MRE is operably linked (such as a CMV gene that is essential or augmenting for growth in vivo) is repressed by a miRNA silencing mechanism such as the RISC.
[0080] Mutation: As used herein, the term "mutation" refers to any difference in a nucleic acid or polypeptide sequence from a normal, consensus, or "wild type" sequence. A mutant is any protein or nucleic acid sequence comprising a mutation. In addition, a cell or an organism with a mutation may also be referred to as a mutant. Some types of coding sequence mutations include point mutations (differences in individual nucleotides or amino acids); silent mutations (differences in nucleotides that do not result in an aminoacid changes); deletions (differences in which one or more nucleotides or amino acids are missing, up to and including a deletion of the entire coding sequence of a gene); frameshift mutations (differences in which deletion of a number of nucleotides indivisible by 3 results in an alteration of the amino acid sequence). A mutation that results in a difference in an amino acid may also be called an amino acid substitution mutation. Amino acid substitution mutations may be described by the amino acid change relative to wild type at a particular position in the amino acid sequence.
[0081] Nucleotide sequences or nucleic acid sequences: The terms "nucleotide sequences" and "nucleic acid sequences" refer to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequences, including, without limitation, messenger RNA (mRNA), DNA / RNA hybrids, or synthetic nucleic acids. The nucleic acid may be singlestranded, or partially or completely double stranded (duplex). Duplex nucleic acids may be homoduplex or heteroduplex.
[0082] Non-Human Primate Cytomegalovirus: The terms "non-human primate cytomegalovirus" or "NHP CMV" as used herein refers to relatives of human cytomegalovirus that are isolated from non-human primates. Specifically, non-human primates that belong to the Cercopithecidae family.
[0083] Operably Linked: As the term "operably linked" is used herein, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in such a way that it has an effect upon the second nucleic acid sequence. Operably linked DNA sequences may be contiguous, or they may operate at a distance.
[0084] Ortholog: As used herein, the term "ortholog" refers to genes or proteins which are homologs via speciation, e.g., closely related and assumed to have common descent based on structural and functional considerations. Orthologous proteins function as recognizably the same activity in different species.
[0085] Promoter: As used herein, the term "promoter" may refer to any of a number of nucleic acid control sequences that directs transcription of a nucleic acid. Typically, a eukaryotic promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element or any other specific DNA sequence that is recognized by one or more transcription factors. Expression by a promoter may be further modulated by enhancer or repressor elements. Numerous examples of promoters are available and well known to those of ordinary skillin the art. A nucleic acid comprising a promoter operably linked to a nucleic acid sequence that codes for a particular polypeptide may be termed an expression vector.
[0086] Recombinant: As used herein, the term "recombinant" with reference to a nucleic acid or polypeptide refers to one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence, for example a CMV vector comprising a heterologous antigen. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. A recombinant polypeptide may also refer to a polypeptide that has been made using recombinant nucleic acids, including recombinant nucleic acids transferred to a host organism that is not the natural source of the polypeptide (for example, nucleic acids encoding polypeptides that form a CMV vector comprising a heterologous antigen).
[0087] Pharmaceutically acceptable carriers: As used herein, a "pharmaceutically acceptable carrier" of use is conventional. Remington's Pharmaceutical Sciences, by E.W. Martin, Mack Publishing Co., Easton, PA, 19th Edition, 1995, describes compositions and formulations suitable for pharmaceutical delivery of the compositions disclosed herein. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, or the like as a vehicle. For solid compositions (such as powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers may include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered may contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
[0088] Polynucleotide: As used herein, the term "polynucleotide" refers to a polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). A polynucleotide is made up of four bases; adenine, cytosine, guanine, and thymine / uracil (uracil is used in RNA). A coding sequence from a nucleic acid is indicative of the sequence of the protein encoded by the nucleic acid.
[0089] Polypeptide: The terms "protein", "peptide", "polypeptide", and "amino acid sequence" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer may be linear or branched, it may comprise modified amino acids or amino acid analogs, and it may be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component.
[0090] Sequence identity / similarity: As used herein, the identity / similarity between two or more nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity or similarity between the sequences. Sequence identity may be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are. Sequence similarity may be measured in terms of percentage identity or similarity (which takes into account conservative amino acid substitutions); the higher the percentage, the more similar the sequences are. Polypeptides or protein domains thereof that have a significant amount of sequence identity and also function the same or similarly to one another (for example, proteins that serve the same functions in different species or mutant forms of a protein that do not change the function of the protein or the magnitude thereof) may be called "homologs."
[0091] Methods of alignment of sequences for comparison are well known in the art.Various programs and alignment algorithms are described in: Smith & Waterman, Adv ApplMath 2, 482 (1981); Needleman & Wunsch, J Mol Biol 48, 443 (1970); Pearson & Lipman, Proc Natl Acad Sci USA 85, 2444 (1988); Higgins & Sharp, Gene 73, 237-244 (1988); Higgins & Sharp, CABIOS 5, 151-153 (1989); Corpet et al, Nuc Acids Res 16, 10881-10890 (1988); Huang et al, Computer App Biosci 8, 155-165 (1992); and Pearson et al, Meth Mol Bio 24,307-331 (1994). In addition, Altschul et al, J Mol Biol 215, 403- 410 (1990), presents a detailed consideration of sequence alignment methods and homology calculations.
[0092] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al, (1990) supra) is available from several sources, including the National Center for Biological Information (NCBI, National Library of Medicine, Building 38 A, Room 8N805, Bethesda, MD 20894) and on the Internet, for use in connection with the sequenceanalysis programs blastp, blastn, blastx, tblastn and tblastx. Additional information may be found at the NCBI web site.
[0093] BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.
[0094] Once aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is presented in both sequences. The percent sequence identity is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence, or by an articulated length (such as 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100. For example, a nucleic acid sequence that has 1166 matches when aligned with a test sequence having 1154 nucleotides is 75.0 percent identical to the test sequence (1166=1554*100=75.0). The percent sequence identity value is rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while 75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The length value will always be an integer. In another example, a target sequence containing a 20-nucleotide region that aligns with 20 consecutive nucleotides from an identified sequence as follows contains a region that shares 75 percent sequence identity to that identified sequence (that is, 15=20*100=75).
[0095] For comparisons of amino acid sequences of greater than about 30 amino acids, the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). Homologs are typically characterized by possession of at least 70% sequence identity counted over the full-length alignment with an amino acid sequence using the NCBI Basic Blast 2.0, gapped blastp with databases such as the nr database, swissprot database, and patented sequences database. Queries searched with the blastn program are filtered with DUST (Hancock & Armstrong, Comput Appl Biosci 10, 67-70 (1994.) Other programs use SEG. In addition, a manual alignment may be performed. Proteins with even greater similarity will show increasing percentage identities when assessed by this method, such as at least about 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to a protein.
[0096] When aligning short peptides (fewer than around 30 amino acids), the alignment is performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequence will show increasing percentage identities when assessed by this method, such as at least about 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to a protein. When less than the entire sequence is being compared for sequence identity, homologs will typically possess at least 75% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85%, 90%, 95% or 98% depending on their identity to the reference sequence. Methods for determining sequence identity over such short windows are described at the NCBI web site.
[0097] One indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions, as described above. Nucleic acid sequences that do not show a high degree of identity may nevertheless encode identical or similar (conserved) amino acid sequences, due to the degeneracy of the genetic code. Changes in a nucleic acid sequence may be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein. Such homologous nucleic acid sequences can, for example, possess at least about 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% sequence identity to a nucleic acid that encodes a protein.
[0098] Subject: As used herein, the term "subject" refers to a living multi-cellular vertebrate organisms, a category that includes both human and non-human mammals.
[0099] Supertope: As used herein, the term "supertope" or "supertope peptide" refers to an epitope or peptide that is recognized by T cells in greater than about 90% of the population regardless of MHC haplotype, i.e., in the presence or absence of given MHC-I, MHC-II, or MHC-E alleles.
[0100] Treatment: As used herein, the term "treatment" refers to an intervention that ameliorates a sign or symptom of a disease or pathological condition. As used herein, the terms "treatment", "treat" and "treating," with reference to a disease, pathological condition or symptom, also refers to any observable beneficial effect of the treatment. The beneficial effect may be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, a reduction in thenumber of relapses of the disease, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease. A prophylactic treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs, for the purpose of decreasing the risk of developing pathology. A therapeutic treatment is a treatment administered to a subject after signs and symptoms of the disease have developed.
[0101] Vaccine: An immunogenic composition that can be administered to a mammal, such as a human, to confer immunity, such as active immunity, to a disease or other pathological condition. Vaccines can be used prophylactically or therapeutically. Thus, vaccines can be used reduce the likelihood of developing a disease (such as a tumor or pathological infection) or to reduce the severity of symptoms of a disease or condition, limit the progression of the disease or condition (such as a tumor or a pathological infection), or limit the recurrence of a disease or condition (such as a tumor). In particular embodiments, a vaccine is a replication-deficient CMV expressing a heterologous antigen, such as a tumor associated antigen derived from a tumor of the lung, prostate, ovary, breast, colon, cervix, liver, kidney, bone, or a melanoma.
[0102] Vector: Nucleic acid molecules of particular sequence can be incorporated into a vector that is then introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art, including promoter elements that direct nucleic acid expression. Vectors can be viral vectors, such as CMV vectors. Viral vectors may be constructed from wild type or attenuated virus, including replication deficient virus.II. Recombinant CMV Vectors
[0103] Disclosed herein are recombinant non-human primate (NHP) cytomegalovirus (CMV) vectors comprising one or more heterologous antigens, that do not express an ortholog of TRS1, but express TRS1 and / or IRS1 of human cytomegalovirus.
[0104] Disclosed herein are recombinant non-human primate cytomegalovirus vectors comprising one or more heterologous antigens, that do not express active UL128, UL130, UL146, UL147, or an ortholog thereof, and do not express an ortholog of TRS1, but expresses active TRS1 and / or IRS1 from human cytomegalovirus.
[0105] In some aspects, wherein the recombinant non-human primate cytomegalovirus vector expresses active TRS1 and / or IRS1 from human cytomegalovirus but does not express an active ortholog of UL128, UL130, UL146, UL147, TRS1, and / or IRS1, due to one or more mutations in the nucleic acid sequence encoding orthologs of ULI 28, UL130, UL146, UL147, TRS1, and / or IRS1.
[0106] In some aspects, the recombinant non-human primate cytomegalovirus vector expresses active TRS1 and / or IRS1 from human cytomegalovirus and expresses UL40 and / or US28, or an ortholog thereof. In some aspects, the recombinant non-human primate cytomegalovirus vector expresses active TRS1 and / or IRS1 from human cytomegalovirus but does not express UL82 (pp71), or an ortholog thereof.
[0107] In some aspects, the recombinant non-human primate cytomegalovirus vector expresses active TRS1 and / or IRS1 derived from human cytomegalovirus but does not express glycoprotein L (gL), or an ortholog thereof.
[0108] Disclosed herein are recombinant rhesus macaque cytomegalovirus (RhCMV) vectors comprising one or more heterologous antigens, that do not express an ortholog of TRS1, but express TRS1 and / or IRS1 from HCMV.
[0109] Disclosed herein are recombinant RhCMV vectors comprising one or more heterologous antigens, that do not express active ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof, and do not express an ortholog of TRS1, but expresses active TRS1 and / or IRS1 from HCMV.
[0110] In some aspects, wherein the recombinant RhCMV vector expresses active TRS1 and / or IRS1 from HCMV but does not express an active Rh230 or an active ortholog of ULI 28, ULI 30, ULI 46, ULI 47 due to one or more mutations in the nucleic acid sequence encoding Rh230, or orthologs of UL128, UL130, UL146, and UL147.
[0111] In some aspects, the recombinant RhCMV vector expresses UL40 and / or US28, or an ortholog thereof. In some aspects, the recombinant RhCMV vector does not express UL82 (pp71), or an ortholog thereof.
[0112] In some aspects, the recombinant non-human primate cytomegalovirus vector expresses active TRS1 and / or I RSI derived from human cytomegalovirus but does not express glycoprotein L (gL), or an ortholog thereof.
[0113] Disclosed herein are recombinant cynomolgus macaque CMV (CyCMV) vectors comprising one or more heterologous antigens, that do not express an Cy230, and expresses TRS1 and / or IRS1 from HCMV.
[0114] Disclosed herein are recombinant CyCMV vectors comprising one or more heterologous antigens, that do not express active ULI 28, U I 30, ULI 46, ULI 47, or an ortholog thereof, do not express Cy230, and expresses active TRS1 and / or IRS1 from HCMV.
[0115] In some aspects, wherein the recombinant CyCMV vector does not express an active Cy230 and does not express ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof, due to one or more mutations in the nucleic acid sequence encoding Cy230, or ULI 28, ULI 30, ULI 46, and ULI 47 or an ortholog thereof.
[0116] In some aspects, the recombinant CyCMV vector expresses TRS1 and / or IRS1 from HCMV and expresses UL40 and / or US28, or an ortholog thereof. In some aspects, the recombinant CyCMV vector does not express UL82 (pp71), or an ortholog thereof.
[0117] In some aspects, the recombinant CyCMV vector expresses active TRS1 and / or IRS1 derived from human cytomegalovirus but does not express glycoprotein L (gL), or an ortholog thereof.
[0118] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active orthologs of ULI 28, ULI 30, ULI 46, ULI 47, and TRS1, but expresses an active TRS1 and / or IRS1 from HCMV, and expresses UL40 and / or US28, or an ortholog thereof. In some aspects, the recombinant CMV vector does not express UL82, or an ortholog thereof.
[0119] In some aspects, the active TRS1 protein has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to SEQ ID NO: 1. In some aspects, the active TRS1 has the sequence of SEQ ID NO: 1.
[0120] In some aspects, the active IRS1 protein has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to SEQ ID NO: 2. In some aspects, the active IRS1 has the sequence of SEQ ID NO: 2.
[0121] In some aspects, the active Rh230 protein has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to SEQ ID NO: 3. In some aspects, the active Rh230 has the sequence of SEQ ID NO: 3.
[0122] In some aspects, the active Cy230 protein has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%identity to SEQ ID NO: 4. In some aspects, the active Cy230 has the sequence of SEQ ID NO: 4.
[0123] The sequences of TRS1, IRS1, Rh230, and Cy230 are provided in Table 1.Table 1. TRS1, IRS1, Rh230, and Cy230 sequencesSEQ ID Protein SequenceNO1 TRS1 maqrngmsprppplgrgrgaggpsgvgssrsssleatstagtststagtatpahavhrveprgp pgappgsgnnstfwhgperlllsqipverqalteleyqamgavwraaflanstgramrkwsq rdagtllplgrpygfyarvtprsqmngvgatdlrqlsprdawivlvatvvhevdpaadptvgd kaghpeglcaqdglylalgagfrvfvydlanntlilaardadewfrhgagevvrlyrcnrlgvgt pratllpqpalrqtllraeeatalgrelrrrwagttvalqtpgrrlqpmvllgawqelaqyepfasa phpaslltavrrhlnqrlccgwlalgavlpsrwlrcaagpatgttagttttmtagttamatgttllpg asgteteaaggdapcamagavgsavtlppqpygaaggsaicvpnadahavvgtdaaaaaaa aptvmvgptamagpaasgtvpramlvvvldelgavfgycpldghvyplaaelshflragvlg alalgresapaaeaarrllpeldreqwerprwdalhlhpraalwarephgqlafllrpgrgeaevl tlatkhpaicanvedylqdarrradaqalgldlatvvmeaggqmihkkakkpkgkedeslm ngkhsrytrpteppltpqaslgralrrddedwkpprlpgedswydldetfwvlgsnrkndvyq rrwkktvlrcgl ei drpmptvpkgcrpqtfthegi qlmggatqepl dtgly ap shvtsafvp sv ympptvpypdpaarlcrdmrrvtfsnvathyhynaq2 IRS1 maqrngmsprppplgrgrgaggpsgvgssrsssleatstagtststagtatpahavhrveprgp pgappgsgnnstfwhgperlllsqipverqalteleyqamgavwraaflanstgramrkwsq rdagtllplgrpygfyarvtprsqmngvgatdlrqlsprdawivlvatvvhevdpaadptvgd kaghpeglcaqdglylalgagfrvfvydlanntlilaardadewfrhgagevvrlyrcnrlgvgt pratllpqpalrqtllraeeatalgrelrrrwagttvalqtpgrrlqpmvllgawqelaqyepfasa phpaslltavrrhlnqrlccgwlalgavlpsrwlrcaagpatgttagttttmtagttamatgttllpg asgteteaaggdapcamagavgsavtlppqpygaaggsaicvpnadahavvgtdaaaaaaa aptvmvgptamagpaasgtvpramlvvvldelgavfgycpldghvyplaaelshflragvlg alalgresapaaeaarrllpeldreqwerprwdalhlhpraalwarephgqwefmfreqrgdp indpvafrlsdartlgldlttvmterqsqlpekyigfyqirkppwlmeqppppsrqtkpdaatlp pplsaqasvshalryddelwrplstvhdhkawldldeshwvlgdsrpddirqrrllkatqrrga eidrpmpvvpeecydqrftteghqviplcasepedddedptydelpsrppqkhkppdkpprlcktgpgppplppkqrhgstdgkvsaprqsehhkrqtrpprppppkfgdrtaahlsqnmrdm yldmctssahrprppapprpkkcqthaphhvhh3 Rh230 mrphrsphswqhlryaglrtspdphshrlpappthwrphqpsplhhmsslmhalptpphqp tsamhppthapgapttltlpsldtrtrlasippqqhaltkdefllmatawadafianttaratrkwc qrqtgqllplgrpanfyavvtprshmrdvgatdlrqlsptddwivlvatlvhemspspqdpptl crheglflaigchfrvflfdlprhtlhlaatdaddffrhgigdlprvyacptlppltvhppepvells rtwpnaaaaaaaightaagqticlqtpgrppqpcllttcweeverwlpfckwphagsivaavr nfiserlccafhllgivtthpwleylsewaaaranwfdtrsmpsrehtrlaayqgstvkrrpkpn khsrhnapasdvppaatpgpaaaaaaatvthspkchaerksderaevdddgrlleknplavm liiidelgvvygyctydglvyplaedlshflrvgllaaltagyaaaspdqaavrllpdqdpyvwe rprpdalylwprpsggprdlasqfafltrpgrwrldtdtstcqsrdedgwrvrdaqalalpaeag qepipqsdqalvsralrfdlrywklpsgpeededpgeddsftllpyrtwaagdynphwdpqs vrgpntvmqrricnhraranrpfrrplpiqprdrdpsvfpkyssdgvlivpc4 Cy230 mrphrsphswqqlryaglrnspdphshrlpapphhwrphppsplhhmsglmqalptpppq tpaamhppahapgapttltlpsidtrtrlasipaqqhaltkdeflimatawadafianttaratrk wcqrqtgqllplgrpanfyavvtprshmrdvgatdlrqlsptddwivlvativhemsptpqdp ptlcrheglflaigchfrvflfdlprhtlhlaatdaddffrhgigdlarvyacptlppltvhppepve llsrtwpsasaaaaavghsaaghticlqtpgrtpqpwllttsweeverwqpfckwphagsiva avrnfiserlcctfhllgivtthpwleylsewaaaranwfdtrsmpsreharlaayqgntvkrrp kpnkhsrhnapasdvptvptpapaaaaathspkchaelpsderaevdddgrlleknplavml iiidelgvvygyctydgliyplaedlshflrvgllaaltagyaaassdqaavrllpdqdpyvwer prpdalylwprpsggprdlpsqfafltrparwrldtdtstcqsrdedgwrvrdaqalalpaeagq epipqsdqalvsralrydlrywklpsgpeededpgeddsfnllpyrtwaagdynphwdpqs vrgpntvmqrricnhraranrpfrrplpiqprdrdpsvfpkystdgvlitpc
[0124] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) further comprises a nucleic acid sequence encoding a microRNA (miRNA) recognition element (MRE). In some aspects, the MRE may be any miRNA recognition element that silences expression in the presence of a miRNA expressed by endothelial cells. In some aspects, the MRE may be any miRNA recognition element that silences expression in the presence of a miRNA expressed by myeloid cells. Such an MRE may be the exact complement of a miRNA. Alternatively, other sequences may be used as MREs for a given miRNA. For example, MREs may be predicted from sequences. In someaspects, the miRNA may be searched on the website microRNA.org (www.microrna.org). In turn, a list of mRNA targets of the miRNA will be listed. For each listed target on the page, 'alignment details' may be accessed and putative MREs accessed.
[0125] One of ordinary skill in the art may select a validated, putative, or mutated MRE sequence from the literature that would be predicted to induce silencing in the presence of a miRNA expressed in a myeloid cell such as a macrophage. One example involves the above referenced website. The person of ordinary skill in the art may then obtain an expression construct whereby a reporter gene (such as a fluorescent protein, enzyme, or other reporter gene) has expression driven by a promoter such as a constitutively active promoter or cell specific promoter. The MRE sequence may then be introduced into the expression construct. The expression construct may be transfected into an appropriate cell, and the cell transfected with the miRNA of interest. A lack of expression of the reporter gene indicates that the MRE silences gene expression in the presence of the miRNA.
[0126] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) further comprises a nucleic acid sequence encoding a microRNA (miRNA) recognition element (MRE), wherein the MRE contains target sites for microRNAs expressed in endothelial cells. In some aspects, the MRE is specific for the miRNA selected from the group consisting of miR126, miR-126-3p, miR-130a, miR-210, miR- 221 / 222, miR-378, miR-296, and miR-328.
[0127] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active orthologs of ULI 28, ULI 30, ULI 46, ULI 47, and TRS1 or an ortholog thereof, expresses an ortholog of active TRS1 and / or IRS1 from HCMV, and comprises an MRE containing target sites for microRNAs expressed in endothelial cells. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active orthologs of ULI 28, ULI 30, ULI 46, UL147, and TRS1, and expresses active TRS1 and / or IRS1 from HCMV, and comprises a MRE specific for miR126.
[0128] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) further comprises a nucleic acid sequence encoding a microRNA (miRNA) recognition element (MRE), wherein the MRE contains target sites for microRNAs expressed in myeloid cells. In some aspects, the MRE is specific for the miRNA selectedfrom the group consisting of miR-142-3p, miR-223, miR-27a, miR-652, miR-155, miR- 146a, miR-132, miR-21, and miR-125.
[0129] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active UL128, UL130, UL146, UL147, TRS1, or an ortholog thereof, and expresses TRS1 and / or IRS1 from HCMV, and comprises an MRE containing target sites for microRNAs expressed in myeloid cells. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active ULI 28, ULI 30, ULI 46, ULI 47, TRS1, or an ortholog thereof, expresses an ortholog of active TRS1 and / or IRS1 from HCMV, and comprises a MRE specific for miR-142-3p.
[0130] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active UL128, ULI 30, ULI 46, ULI 47, TRS1, or an ortholog thereof, expresses an ortholog of active TRS1 and / or IRS1 from HCMV, expresses UL40 and / or US28, or an ortholog thereof, and does not express UL82, or an ortholog thereof, and comprises an MRE containing target sites for microRNAs expressed in myeloid cells. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV) comprises one or more heterologous antigens, does not express active ULI 28, ULI 30, ULI 46, ULI 47, TRS1, or an ortholog thereof, expresses an ortholog of active TRS1 and / or IRS1 from HCMV, expresses UL40 and / or US28, or an ortholog thereof, and does not express UL82, or an ortholog thereof, and comprises a MRE specific for miR-142-3p.
[0131] In aspects embodiments, the one or more heterologous antigens may be a pathogen specific antigen, a tumor antigen, a tumor specific antigen, or a host selfantigen. In some aspects, the host self-antigen is derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.
[0132] The pathogen specific antigen may be derived from, for example, human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2 , hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, Clostridium tetani, and Mycobacterium tuberculosis.
[0133] In some aspects, the pathogen specific antigen is a MHC-E supertope. In some aspects, the MHC-E supertope is a HIV epitope. In some aspects, the MHC-E supertope has a sequence having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%identity to the sequence of any one of SEQ ID NOs: 5-24. In some aspects, the MHC-E supertope has the sequence of any one of SEQ ID NOs: 5-24. In some aspects, one or more of the MHC-E supertopes are used to generate a fusion protein. The fusion protein may contain one or more of the MHC-E supertopes, in any order. The sequences of the MHC-E supertopes are provided in Table 2.Table 2. List of MHC-E HIV supertopesAntigen Peptide Sequence (15mer) SEQ ID NOs:(optimal minimal peptide (full peptide sequence, optimal sequence is underlined) minimal peptide sequence) HIVgag LDAWEKIRLRPGGKK 5, 6KKAQQAAADTGNSSQ 7, 8QMVHQAISPRTLNAW 9, 10NTMLNTVGGHQAAMQ 11, 12STLQEQIGWMTNNPP 13, 14IVRMYSPVSILDIRQ 15, 16QKQEPIDKELYPLAS 17, 18HIVpol SFSFPQITLWQRPLV 19VRQYDQILIEICGKK 20EPFRKQNPDIVIYQL 21YVDGAANRETKLGKA 22EEHEKYSNWRAMAS 23HIVnef ILDLWVYHTQGYFPD 24
[0134] Tumor antigens are relatively restricted to tumor cells and can be any protein that induces an immune response. However, many tumor antigens are host (self) proteins and thus are typically not seen as antigenic by the host immune system. Tumor antigens can also be abnormally expressed by cancer cells. Tumor antigens can also be germline / testis antigens expressed in cancer cells, cell lineage differentiation antigens not expressed in adult tissue, or antigens overexpressed in cancer cells. Tumor antigens include, but are not limited to, prostatic acidic phosphatase (PAP); Wilms tumor suppressor protein (WT1); Mesothelin (MSLN); Her-2 (HER2); human papilloma virus antigen E6 of strain HPV16; human papilloma virus antigen E7 of strain HPV16; human papilloma virusantigen E6 of strain HPV18; Human papilloma virus antigen E7 of strain HPV18; a fusion protein of human papilloma virus E6 and E7 from HPV16 and HPV18; mucin 1 (MUC1); LMP2; epidermal growth factor receptor (EGFR); p53; New York esophagus 1 (NY-ESO-1); prostate specific membrane antigen (PSMA); GD2, carcinoembryonic antigen (CEA); melanoma antigen a / melanoma antigen recognized by T cells 1 (MelanA / MARTl); Ras; gplOO, Proteinase 3 (PR1), Bcr-abl; Survivin; prostate specific antigen (PSA); human telomerase reverse transcriptase (hTERT); EphA2; ML-IAP; alphafetoprotein (AFP); EpCAM; ERG; NA 17; PAX3; ALK; Androgen receptor (AR); Cyclin Bl; MYCN; RhoC; tyrosine related protein 2 (TRP-2); GD3; Fucosyl GM1; PSCA; sLe(a); CYP1B1; PLCA1; GM3; BORIS; Tn; GloboH; Ets variant gene 6 / acute myeloid leukemia 1 gene ETS (ETV6-AML); NY-BR-1; RGS5; squamous antigen rejecting tumor or 3 (SART3); STn; Carbonic anhydrase IX; PAX5; OY-TES1; Sperm protein 17; LCK; HMWMAA; AKAP-4; SSX2; B7H3; Legumain; Tie 2; Page4;VEGFR2; MAD-CT-1; FAP; PDGFR; MAD-CT-2; Fosrelated antigen 1; TAG-72; 9D7; EphA3; Telomerase; SAP-1; BAGE family; CAGE family; GAGE family; MAGE family; SAGE family; XAGE family; preferentially expressed antigen of melanoma (PRAME); melanocortin 1 receptor (MC1R); P-catenin; BRCA1 / 2; CDK4; chronic myelogenous leukemia 66 (CML66); TGF-p. In certain embodiments, the host selfantigens include prostatic acidic phosphatase, Wilms tumor suppressor protein, mesothelin, orHer-2.
[0135] In some embodiments the tumor antigen is derived from a cancer. The cancer includes, but is not limited to, Acute lymphoblastic leukemia; Acute myeloid leukemia; Adrenocortical carcinoma; AIDS-related cancers; AIDS-related lymphoma; Anal cancer; Appendix cancer; Astrocytoma, childhood cerebellar or cerebral; Basal cell carcinoma; Bile duct cancer, extrahepatic; Bladder cancer; Bone cancer, Osteosarcoma / Malignant fibrous histiocytoma; Brainstem glioma; Brain tumor; Brain tumor, cerebellar astrocytoma; Brain tumor, cerebral astrocytoma / malignant glioma; Brain tumor, ependymoma; Brain tumor, medulloblastoma; Brain tumor, supratentorial primitive neuroectodermal tumors; Brain tumor, visual pathway and hypothalamic glioma; Breast cancer; Bronchial adenomas / carcinoids; Burkitt lymphoma; Carcinoid tumor, childhood; Carcinoid tumor, gastrointestinal; Carcinoma of unknown primary; Central nervous system lymphoma, primary; Cerebellar astrocytoma, childhood; Cerebral astrocytoma / Malignant glioma, childhood; Cervical cancer; Childhood cancers; Chroniclymphocytic leukemia; Chronic myelogenous leukemia; Chronic myeloproliferative disorders; Colon Cancer; Cutaneous T -cell lymphoma; Desmoplastic small round cell tumor; Endometrial cancer; Ependymoma; Esophageal cancer; Ewing's sarcoma in the Ewing family of tumors; Extracranial germ cell tumor, Childhood; Extragonadal Germ cell tumor; Extrahepatic bile duct cancer; Eye Cancer, Intraocular melanoma; Eye Cancer, Retinoblastoma; Gallbladder cancer; Gastric (Stomach) cancer; Gastrointestinal Carcinoid Tumor; Gastrointestinal stromal tumor (GIST); Germ cell tumor: extracranial, extragonadal, or ovarian; Gestational trophoblastic tumor; Glioma of the brain stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Gastric carcinoid; Hairy cell leukemia; Head and neck cancer; Heart cancer; Hepatocellular (liver) cancer; Hodgkin lymphoma; Hypopharyngeal cancer;Hypothalamic and visual pathway glioma, childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi sarcoma; Kidney cancer (renal cell cancer); Laryngeal Cancer; Leukemias; Leukemia, acute lymphoblastic (also called acute lymphocytic leukemia); Leukemia, acute myeloid (also called acute myelogenous leukemia); Leukemia, chronic lymphocytic (also called chronic lymphocytic leukemia); Leukemia, chronic myelogenous (also called chronic myeloid leukemia); Leukemia, hairy cell; Lip and Oral Cavity Cancer; Liver Cancer (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphomas; Lymphoma, AIDS-related; Lymphoma, Burkitt; Lymphoma, cutaneous T -Cell; Lymphoma, Hodgkin; Lymphomas, Non-Hodgkin (an old classification of all lymphomas except Hodgkin's); Lymphoma, Primary Central Nervous System; Marcus Whittle, Deadly Disease; Macroglobulinemia, Waldenstrim; Malignant Fibrous Histiocytoma of Bone / Osteosarcoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma, Adult Malignant; Mesothelioma, Childhood; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma / Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic / Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple (Cancer of the Bone-Marrow); Myeloproliferative Disorders, Chronic; Nasal cavity and paranasal sinus cancer; Nasopharyngeal carcinoma; Neuroblastoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Oral Cancer; Oropharyngeal cancer;Osteosarcoma / malignant fibrous histiocytoma of bone; Ovarian cancer; Ovarian epithelialcancer (Surface epithelial-stromal tumor); Ovarian germ cell tumor; Ovarian low malignant potential tumor; Pancreatic cancer; Pancreatic cancer, islet cell; Paranasal sinus and nasal cavity cancer; Parathyroid cancer; Penile cancer; Pharyngeal cancer;Pheochromocytoma; Pineal astrocytoma; Pineal germinoma; Pineoblastoma and supratentorial primitive neuroectodermal tumors, childhood; Pituitary adenoma; Plasma cell neoplasia / Multiple myeloma; Pleuropulmonary blastoma; Primary central nervous system lymphoma; Prostate cancer; Rectal cancer; Renal cell carcinoma (kidney cancer); Renal pelvis and ureter, transitional cell cancer; Retinoblastoma; Rhabdomyosarcoma, childhood; Salivary gland cancer; Sarcoma, Ewing family of tumors; Sarcoma, Kaposi; Sarcoma, soft tissue; Sarcoma, uterine; Sezary syndrome; Skin cancer (nonmelanoma); Skin cancer (melanoma); Skin carcinoma, Merkel cell; Small cell lung cancer; Small intestine cancer; Soft tissue sarcoma; Squamous cell carcinoma— see Skin cancer (nonmelanoma); Squamous neck cancer with occult primary, metastatic; Stomach cancer; Supratentorial primitive neuroectodermal tumor, childhood; T -Cell lymphoma, cutaneous (Mycosis Fungoides and Sezary syndrome); Testicular cancer; Throat cancer; Thymoma, childhood; Thymoma and Thymic carcinoma; Thyroid cancer; Thyroid cancer, childhood; Transitional cell cancer of the renal pelvis and ureter; Trophoblastic tumor, gestational; Unknown primary site, carcinoma of, adult; Unknown primary site, cancer of, childhood; Ureter and renal pelvis, transitional cell cancer; Urethral cancer; Uterine cancer, endometrial; Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, childhood; Vulvar cancer; Waldenstrom macroglobulinemia and Wilms tumor (kidney cancer.)III. Methods for the Modulation of T Cell Responses by Administration of Recombinant CMV Vectors
[0136] Disclosed herein are methods for the modulation of T cell responses elicited in a subject by a recombinant non-human primate (NHP) CMV vector expressing an active ortholog of HCMV TRS1 and / or IRS1 as disclosed herein. The methods involve administering an effective amount of at least one recombinant CMV vector as disclosed herein comprising one or more heterologous antigens to the subject.
[0137] Disclosed herein are methods for the modulation of T cell responses elicited in a subject by a recombinant non-human primate (NHP) CMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involveadministering an effective amount of at least one recombinant NHP CMV vector as disclosed herein comprising one or more heterologous antigens to the subject. In some aspects, the NHP CMV vector is an RhCMV vector. In some aspects, the NHP CMV vector is a CyCMV vector.
[0138] Disclosed herein are methods for the modulation of T cell responses elicited in a subject by a recombinant RhCMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involve administering an effective amount of at least one recombinant RhCMV vector as disclosed herein comprising one or more heterologous antigens to the subject.
[0139] Disclosed herein are methods for the modulation of T cell responses elicited in a subject by a recombinant CyCMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involve administering an effective amount of at least one recombinant CyCMV vector as disclosed herein comprising one or more heterologous antigens to the subject.
[0140] In some aspects, the subject is a human. In some aspects, the subject is a nonhuman primate.
[0141] Disclosed herein are methods for the modulation of T cell responses elicited in a human by a recombinant non-human primate (NHP) CMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involve administering an effective amount of at least one recombinant NHP CMV vector as disclosed herein comprising one or more heterologous antigens to the human. In some aspects, the NHP CMV vector is an RhCMV vector. In some aspects, the NHP CMV vector is a CyCMV vector.
[0142] Disclosed herein are methods for the modulation of T cell responses elicited in a human by a recombinant RhCMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involve administering an effective amount of at least one recombinant RhCMV vector as disclosed herein comprising one or more heterologous antigens to the human.
[0143] Disclosed herein are methods for the modulation of T cell responses elicited in a human by a recombinant CyCMV vector expressing an active TRS1 and / or an active IRS1 of HCMV as disclosed herein. The methods involve administering an effective amount of at least one recombinant CyCMV vector as disclosed herein comprising one or more heterologous antigens to the human.
[0144] In some aspects, the method further comprises generating an immune response to the one or more heterologous antigens, comprising administering to the subject the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in an amount effective to elicit a CD8+ T cell response to one or more heterologous antigens. In some aspects, the method further comprises treating or preventing cancer in a subject, comprising administering the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens. In some aspects, the method further comprises treating or preventing a pathogenic infection in a subject, comprising administering the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens. In some aspects, the method further comprises treating an autoimmune disease or disorder in a subject, comprising administering to the subject the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
[0145] The mutation may be any mutation that results in a lack of expression of active proteins. Such mutations may include point mutations, frameshift mutations, deletions of less than all of the sequence that encodes the protein (truncation mutations), or deletions of all of the nucleic acid sequence that encodes the protein, or any other mutation.
[0146] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) is administered in an amount effective to elicit a CD8+ T cell response to the at least one heterologous antigen. In some aspects, the CD8+ T cell response elicited by the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) is characterized by having at least 10% of the CD8+ T cells directed against epitopes presented by MHC-E. In some aspects, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the CD8+ T cells are restricted by MHC-E. In some aspects, the CD8+ T cells restricted by MHC-E recognize peptides shared by at least 90% of other subjects immunized with the vector. In some aspects, the CD8+ T cells are directed against a supertope presented by MHC-E.
[0147] In some aspects, the CD8+ T cell response elicited by the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) is characterized by having at least 10% of the CD8+ T cells directed against epitopes presented by MHC-II. In someaspects, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the CD8+ T cells are restricted by MHC-II. In some aspects, the CD8+ T cells restricted by MHC-II recognized peptides shared by at least 90% of other subjects immunized with the vector. In some aspects, the CD8+ T cells are directed against a supertope presented by MHC-II.
[0148] In some aspects, the CD 8+ T cell response elicited by a recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) expressing an active TRS1 and / or IRS1, or an ortholog thereof, and does not express an active US11 or an ortholog thereof is characterized by having at least 10% of the CD8+ T cells directed against epitopes presented by MHC-Ia. In some aspects, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75%, at least 90%, at least 95% or at least 95% of the CD8+ T cells are restricted by MHC-Ia.
[0149] Also disclosed herein are methods of generating CD8+ T cells that recognize MHC-E peptide complexes. This method involves administering to a first subject a recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in an amount effective to generate a set of CD8+ T cells that recognize MHC-E / peptide complexes. The recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) comprises a first nucleic acid sequence encoding one or more heterologous antigens and expresses an active TRS1 and / or IRS1 from HCMV but does not express: an active UL128, or an ortholog thereof, an active ULI 30, or an ortholog thereof, an active ULI 46, or an ortholog thereof, and an active ULI 47, or an ortholog thereof, or an active TRS1 ortholog. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) does not express active UL82, or an ortholog thereof. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) expresses active UL40 and US28 or an orthologs thereof.
[0150] In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) expresses an active TRS1 and / or IRS1 from HCMV and does not express an active ULI 28, ULI 30, ULI 46, ULI 47, or an orthologs thereof, and an ortholog of TRS1 (e.g., Rh230 and Cy230) and comprises a nucleic acid sequence encoding UL40, US28, or an orthologs thereof and a microRNA (miRNA) recognition element (MRE). In some embodiments, the MRE contains target sites for microRNAs expressed in endothelial cells. Examples of such miRNAs expressed in endothelial cellsare miR126, miR-126-3p, miR-130a, miR-210, miR-221 / 222, miR-378, miR-296, and miR-328.
[0151] In some aspects, the one or more heterologous antigens may be any antigen, including a pathogen-specific antigen, a tumor virus antigen, a tumor antigen, or a host self-antigen. In some aspects, the host self-antigen is an antigen derived from the variable region of a T cell receptor or a B cell receptor.
[0152] In some aspects, the method further comprises: identifying a first CD8+ T cell receptor from the set of CD8+ T cells, wherein the first CD8+ T cell receptor recognizes a MHC-E / heterologous antigen-derived peptide complex. In some aspects, the first CD8+ T cell receptor is identified by DNA or RNA sequencing. In some aspects, this method may further comprise transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ T cell receptor and a promoter operably linked to the nucleic acid sequence encoding the T cell receptor, wherein the second CD8+ T cell receptor comprises CDR3a and CDR3P of the first CD8+ T cell receptor, thereby generating one or more transfected CD8+ T cells that recognize a MHC-E / heterologous antigen-derived peptide complex. In some aspects, the one or more CD8+ T cells for transfection with the expression vector may be isolated from the first subject or a second subject.
[0153] In some aspects, the method further comprises identifying a MHC-E restricted CD8+ T cell receptor from CD8+ T cells elicited by a recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) in a human. In some aspects, the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) expresses active TRS1 and / or IRS1, but is defective in expression of UL128, UL130, UL146, UL147, and expresses UL40, US28, and an ortholog of TRS1 (e.g., Rh230 or Cy230). In some aspects, the CD8+ T cell receptor is identified by RNA or DNA sequencing.
[0154] In some aspects, the method further comprises a CD 8+ T cell receptor that recognizes MHC-E supertopes. In some aspects, the MHC-E supertope is a human immunodeficiency virus epitope. In some aspects, the MHC-E supertope has a sequence having at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to any one of SEQ ID NOs: 5-24. In some aspects, the MHC-E supertope has a sequence having the identity of any one of SEQ ID NOs: 5-24.
[0155] Also disclosed is a TCR-transfected CD8+ T cell that recognizes MHC-E-peptide complexes prepared by a process comprising the steps of: (1) administering to a first subject a recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) (deleted for an orthologs of ULI 28, ULI 30, ULI 46, ULI 47, TRS1 and, expressing TRS1 and / or IRS1 from HCMV; in some embodiments, deleted for an ortholog of UL82; expressing UL40 and US28 or orthologs thereof; and, in some embodiments, expressing a nucleic acid sequence encoding a microRNA recognition element) in an amount effective to generate a set of CD8+ T cells that recognize MHC-E / peptide complexes, wherein the recombinant CMV vector comprises one or more heterologous antigens; (2) identifying a first CD8+ T cell receptor from the set of CD8+ T cells, wherein the first CD8+ T cell receptor recognizes a MHC-E / heterologous antigen-derived peptide complex; (3) isolating one or more CD8+ T cells from the first subject or a second subject; and (4) transfecting the one or more CD8+T cells isolated from the first or second subject with an expression vector, thereby creating a transfected T cell that recognizes MHC-E peptide complexes wherein the transfected CD8+ T cells generate an immune response to the MHC-E / heterologous antigen-derive peptide complex.
[0156] In some aspects, this method may further comprise transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ T cell receptor and a promoter operably linked to the nucleic acid sequence encoding the T cell receptor, wherein the second CD8+ T cell receptor comprises CDR3a and CDR3P of the first CD8+ T cell receptor, thereby generating one or more transected CD8+ T cells that recognize a MHC- E / heterologous antigen-derived peptide complex. In some aspects, the one or more CD8+ T cells for transfection with the expression vector may be isolated from the first subject or a second subject.
[0157] In some aspects, the first and / or second CD8+ T cell receptors are identified by RNA or DNA sequencing. In some aspects, the first and / or second CD8+ T cell receptor recognizes MHC-E supertopes. In some aspects, the MHC-E supertope is a human immunodeficiency virus epitope. In some aspects, the MHC-E supertope has a sequence having least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identity to any one of SEQ ID NOs: 5-24. In some aspects, the MHC-E supertope has the sequence of any one of SEQ ID NOs: 5-24.
[0158] In some aspects, the nucleic acid sequence encoding the second CD8+ TCR is identical to the nucleic acid sequence encoding the first CD8+ TCR. In some aspects, the first and / or second subject is a human or nonhuman primate. In some aspects, the second CD8+ TCR is a chimeric CD8+ TCR. In some aspects, the first subject is a nonhuman primate and the second subject is a human, and wherein the second CD8+ TCR is a chimeric nonhuman primate-human CD8+ TCR comprising the non-human primate CDR3a and CDR3P of the first CD8+ TCR. In some aspects, the second CD8+ TCR comprises the nonhuman primate CDRla, CDR2a, CDR3a, CDRip, CDR2P, and CDR3P of the first CD8+ TCR. In some aspects, the second CD8+ TCR comprises the CDRla, CDR2a, CDR3a, CDRip, CDR2P, and CDR3P of the first CD8+ TCR.
[0159] Also disclosed herein are methods of treating a disease, such as cancer, a pathogenic infection, or an immune disease or disorder, the method comprising administering the transfected T cell that recognizes MHC-E peptide complexes to the first or second subject. Also disclosed herein are methods of inducing an immune response to a host self-antigen or tissue-specific antigen, the method comprising administering the transfected T cell that recognizes MHC-E peptide complexes to the first or second subject.
[0160] The cancer, includes but is not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, mesothelioma, malignant mesothelioma, kidney cancer, cervical cancer, oropharyngeal cancer, anal cancer, penile cancer, vaginal cancer, vulvar cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma, and germ cell tumors.
[0161] The pathogenic infection, includes but is not limited to, human immunodeficiency virus, herpes simplex virus type I, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
[0162] The recombinant CMV vectors vector (e.g., NHP CMV, RhCMV, or CyCMV vector) disclosed herein may be used as an immunogenic, immunological or vaccine composition containing the recombinant CMV virus or vector (e.g., NHP CMV, RhCMV, or CyCMV vector), and a pharmaceutically acceptable carrier or diluent. An immunological composition containing the recombinant CMV virus or vector (or an expression product thereof) (e.g., NHP CMV, RhCMV, or CyCMV vector) elicits animmunological response— local or systemic. The response can, but need not be, protective. An immunogenic composition containing the recombinant CMV virus or vector (or an expression product thereof) (e.g., NHP CMV, RhCMV, or CyCMV vector) likewise elicits a local or systemic immunological response which can, but need not be, protective. A vaccine composition elicits a local or systemic protective response. Accordingly, the terms "immunological composition" and "immunogenic composition" include a "vaccine composition" (as the two former terms may be protective compositions).
[0163] The recombinant CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) disclosed herein may be used in methods of inducing an immunological response in a subject comprising administering to the subject an immunogenic, immunological or vaccine composition comprising the recombinant CMV virus or vector (e.g., NHP CMV, RhCMV, or CyCMV vector) and a pharmaceutically acceptable carrier or diluent. For purposes of this specification, the term "subject" includes all animals, including nonhuman primates and humans, while "animal" includes all vertebrate species, except humans; and "vertebrate" includes all vertebrates, including animals (as "animal" is used herein) and humans. And, of course, a subset of "animal" is "mammal", which for purposes of this specification includes all mammals, except humans.
[0164] The recombinant CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) disclosed herein may be used in therapeutic compositions containing the recombinant CMV virus or vector (e.g., NHP CMV, RhCMV, or CyCMV vector) and a pharmaceutically acceptable carrier or diluent. The CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) disclosed herein may be prepared by inserting DNA comprising a sequence that encodes the tumor antigen into an essential or non-essential region of the CMV genome. The method may further comprise deleting one or more regions from the CMV genome. The method may comprise in vivo recombination. Thus, the method may comprise transfecting a cell with CMV DNA in a cell-compatible medium in the presence of donor DNA comprising the heterologous DNA flanked by DNA sequences homologous with portions of the CMV genome, whereby the heterologous DNA is introduced into the genome of the CMV, and optionally then recovering CMV modified by the in vivo recombination. The method may also comprise cleaving CMV DNA to obtain cleaved CMV DNA, ligating the heterologous DNA to the cleaved CMV DNA to obtain hybrid CMV-heterologous DNA, transfecting a cell with the hybrid CMV-heterologous DNA, and optionally then recovering CMV modified bythe presence of the heterologous DNA Since in vivo recombination is comprehended, the method accordingly also provides a plasmid comprising donor DNA not naturally occurring in CMV encoding a polypeptide foreign to CMV, the donor DNA is within a segment of CMV DNA that would otherwise be co-linear with an essential or non- essential region of the CMV genome such that DNA from an essential or nonessential region of CMV is flanking the donor DNA The heterologous DNA may be inserted into CMV to generate the recombinant CMV in any orientation that yields stable integration of that DNA, and expression thereof, when desired.
[0165] The DNA encoding the heterologous antigen in the recombinant CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) may also include a promoter. The promoter may be from any source such as a herpes virus, including an endogenous cytomegalovirus (CMV) promoter, such as a human CMV (HCMV), rhesus macaque CMV (RhCMV), murine, or other CMV promoter. The promoter may also be a nonviral promoter such as the EFla promoter. The promoter may be a truncated transcriptionally active promoter which comprises a region transactivated with a transactivating protein provided by the virus and the minimal promoter region of the full-length promoter from which the truncated transcriptionally active promoter is derived. The promoter may be composed of an association of DNA sequences corresponding to the minimal promoter and upstream regulatory sequences. A minimal promoter is composed of the CAP site plus ATA box (minimum sequences for basic level of transcription; unregulated level of transcription); "upstream regulatory sequences" are composed of the upstream element(s) and enhancer sequence(s). Further, the term "truncated" indicates that the full-length promoter is not completely present, i.e., that some portion of the full-length promoter has been removed. And, the truncated promoter may be derived from a herpesvirus such as MCMV or HCMV, e.g., HCMV-IE or MCMV-IE. There may be up to a 40% and even up to a 90% reduction in size, from a full-length promoter, based upon base pairs. The promoter may also be a modified non-viral promoter. As to HCMV promoters, reference is made to U.S. Pat. Nos. 5,168,062 and 5,385,839. As to transfecting cells with plasmid DNA for expression therefrom, reference is made to Feigner et al. (1994), J Biol. Chem.269, 2550-2561. And, as to direct injection of plasmid DNA as a simple and effective method of vaccination against a variety of infectious diseases reference is made to Science, 259:1745-49, 1993. It is therefore within the scope of this disclosure that the vector may be used by the direct injection of vector DNA.
[0166] Also disclosed is an expression cassette that may be inserted into a recombinant virus or plasmid comprising the truncated transcriptionally active promoter. The expression cassette may further include a functional truncated polyadenylation signal; for instance an SV40 polyadenylation signal which is truncated, yet functional. Considering that nature provided a larger signal, it is indeed surprising that a truncated polyadenylation signal is functional. A truncated polyadenylation signal addresses the insert size limit problems of recombinant viruses such as CMV. The expression cassette may also include heterologous DNA with respect to the virus or system into which it is inserted; and that DNA may be heterologous DNA as described herein.
[0167] As to antigens for use in vaccine or immunological compositions, see also Stedman's Medical Dictionary (24th edition, 1982, e.g., definition of vaccine (for a list of antigens used in vaccine formulations); such antigens or epitopes of interest from those antigens may be used. As to tumor antigens, one skilled in the art may select a tumor antigen and the coding DNA therefor from the knowledge of the amino acid and corresponding DNA sequences of the peptide or polypeptide, as well as from the nature of particular amino acids (e.g., size, charge, etc.) and the codon dictionary, without undue experimentation.
[0168] One method to determine T epitopes of an antigen involves epitope mapping.Overlapping peptides of the tumor antigen are generated by oligo-peptide synthesis. The individual peptides are then tested for their ability to induce T cell activation. This approach has been particularly useful in mapping T cell epitopes since the T cell recognizes short linear peptides complexed with MHC molecules.
[0169] An immune response to a tumor antigen is generated, in general, as follows: T cells recognize proteins only when the protein has been cleaved into smaller peptides and is presented in a complex called the "major histocompatibility complex (MHC)" located on another cell's surface. There are two classes of MHC complexes— class I and class II, and each class is made up of many different alleles. Different species, and individual subjects have different types of MHC complex alleles; they are said to have a different MHC type. One type of MHC class I molecule is called MHC-E (HLA-E in humans, Mamu-E in RM, Qa-lb in mice). Unlike other MHC -I molecules, MHC-E is highly conserved within and between mammalian species.
[0170] It is noted that the DNA comprising the sequence encoding the tumor antigen may itself include a promoter for driving expression in the CMV vector (e.g., NHP CMV,RhCMV, or CyCMV vector) or the DNA may be limited to the coding DNA of the tumor antigen. This construct may be placed in such an orientation relative to an endogenous CMV promoter that it is operably linked to the promoter and is thereby expressed.Further, multiple copies of DNA encoding the tumor antigen or use of a strong or early promoter or early and late promoter, or any combination thereof, may be done so as to amplify or increase expression. Thus, the DNA encoding the tumor antigen may be suitably positioned with respect to a CMV endogenous promoter, or those promoters may be translocated to be inserted at another location together with the DNA encoding the tumor antigen. Nucleic acids encoding more than one tumor antigen may be packaged in the CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector).
[0171] Further disclosed are pharmaceutical and other compositions containing the disclosed CMV vectors. Such pharmaceutical and other compositions may be formulated so as to be used in any administration procedure known in the art. Such pharmaceutical compositions may be via a parenteral route (intradermal, intraperitoneal, intramuscular, subcutaneous, intravenous, or others). The administration may also be via a mucosal route, e.g., oral, nasal, genital, etc.
[0172] The disclosed pharmaceutical compositions may be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical arts. Such compositions may be administered in dosages and by techniques well known to those skilled in the medical arts taking into consideration such factors as the breed or species, age, sex, weight, and condition of the particular patient, and the route of administration. The compositions may be administered alone, or may be co-administered or sequentially administered with other CMV vectors or with other immunological, antigenic or vaccine or therapeutic compositions. Such other compositions may include purified native antigens or epitopes or antigens or epitopes from the expression by a recombinant CMV or another vector system; and are administered taking into account the aforementioned factors.
[0173] Examples of compositions include liquid preparations for orifice, e.g., oral, nasal, anal, genital, e.g., vaginal, etc., administration such as suspensions, syrups or elixirs; and, preparations for parenteral, subcutaneous, intraperitoneal, intradermal, intramuscular or intravenous administration (e.g., injectable administration) such as sterile suspensions or emulsions. In such compositions the recombinant may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like.
[0174] Antigenic, immunological or vaccine compositions typically may contain an adjuvant and an amount of the CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) or expression product to elicit the desired response. In human applications, alum (aluminum phosphate or aluminum hydroxide) is a typical adjuvant. Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have toxicities which limit their potential use in human vaccines. Chemically defined preparations such as muramyl dipeptide, monophosphoryllipid A, phospholipid conjugates such as those described by Goodman- Snitkoff et al., J Immunol. 147:410-415 (1991), encapsulation of the protein within a proteoliposome as described by Miller et al., J Exp. Med. 176:1739-1744 (1992), and encapsulation of the protein in lipid vesicles such as Novasome lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be used.
[0175] The composition may be packaged in a single dosage form for immunization by parenteral (e.g., intramuscular, intradermal or subcutaneous) administration or orifice administration, e.g., perlingual (e.g., oral), intragastric, mucosal including intraoral, intraanal, intravaginal, and the like administration. And again, the effective dosage and route of administration are determined by the nature of the composition, by the nature of the expression product, by expression level if recombinant CMV is directly used, and by known factors, such as breed or species, age, sex, weight, condition and nature of host, as well as LD50 and other screening procedures which are known and do not require undue experimentation. Dosages of expressed product may range from a few to a few hundred micrograms, e.g., 5 to 500 pg. The CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) may be administered in any suitable amount to achieve expression at these dosage levels. In nonlimiting examples: CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) may be administered in an amount of at least 102pfu; thus, CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) may be administered in at least this amount; or in a range from about 102pfu to about 10?pfu. Other suitable carriers or diluents may be water or a buffered saline, with or without a preservative. The CMV vector (e.g., NHP CMV, RhCMV, or CyCMV vector) may be lyophilized for resuspension at the time of administration or may be in solution. "About" may mean within 1%, 5%, 10% or 20% of a defined value.
[0176] It should be understood that the proteins and the nucleic acids encoding them of the present disclosure may differ from the exact sequences illustrated and describedherein. Thus, the disclosure contemplates deletions, additions, truncations, and substitutions to the sequences shown, so long as the sequences function in accordance with the methods of the disclosure. In this regard, substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids. For example, amino acids are generally divided into four families: (1) acidic— aspartate and glutamate; (2) basic— lysine, arginine, histidine; (3) nonpolar— alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar— glycine, asparagine, glutamine, cysteine, serine threonine, and tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. It is reasonably predictable that an isolated replacement of leucine with isoleucine or valine, or vice versa; an aspartate with a glutamate or vice versa; a threonine with a serine or vice versa; or a similar conservative replacement of an amino acid with a structurally related amino acid, will not have a major effect on the biological activity. Proteins having substantially the same amino acid sequence as the proteins described but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the scope of the disclosure.
[0177] The nucleotide sequences of the present disclosure may be codon optimized, for example the codons may be optimized for use in human cells. For example, any viral or bacterial sequence may be so altered. Many viruses, including HIV and other lentiviruses, use a large number of rare codons and, by altering these codons to correspond to codons commonly used in the desired subject, enhanced expression of the tumor antigen may be achieved as described in Andreetal., J Virol. 72:1497-1503,1998
[0178] Nucleotide sequences encoding functionally and / or antigenically equivalent variants and derivatives of the CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) and the glycoproteins included therein are contemplated. These functionally equivalent variants, derivatives, and fragments display the ability to retain antigenic activity. For instance, changes in a DNA sequence that do not change the encoded amino acid sequence, as well as those that result in conservative substitutions of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogs are those which will not significantly affect properties of the encoded polypeptide. Conservative amino acid substitutions are glycine / alanine; valine / isoleucine / leucine; asparagine / glutamine; aspartic acid / glutamic acid; serine / threonine / methionine; lysine / arginine; and phenylalanine / tyrosine / tryptophan. Inone embodiment, the variants have at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homology or identity to the antigen, epitope, immunogen, peptide or polypeptide of interest.
[0179] Sequence identity or homology is determined by comparing the sequences when aligned so as to maximize overlap and identity while minimizing sequence gaps. In particular, sequence identity may be determined using any of a number of mathematical algorithms. A nonlimiting example of a mathematical algorithm used for comparison of two sequences is the algorithm of Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1990; 87: 2264-2268, modified as in Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1993;90: 5873-5877.
[0180] Another example of a mathematical algorithm used for comparison of sequences is the algorithm of Myers & Miller, CABIOS 1988;4: 11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 may be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson & Lipman, Proc. Natl. Acad. Sci. USA 1988; 85: 2444-2448.
[0181] Advantageous for use according to the present disclosure is the WU -BLAST (Washington University BLAST) version 2.0 software. WU-BLAST version 2.0 executable programs for several UNIX platforms may be downloaded. This program is based on WU-BLAST version 1.4, which in turn is based on the public domain NCBI - BLAST version 1.4 (Altschul & Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460- 480; Altschul et al., Journal of Molecular Biology 1990; 215: 403-410; Gish & States, 1993; Nature Genetics 3: 266-272; Karlin & Altschul, 1993; Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein).
[0182] The various recombinant nucleotide sequences and antibodies and / or antigens of the disclosure are made using standard recombinant DNA and cloning techniques. Such techniques are well known to those of skill in the art. See for example, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al. 1989).
[0183] The nucleotide sequences of the present disclosure may be inserted into "vectors." The term "vector" is widely used and understood by those of skill in the art, and as used herein the term "vector" is used consistent with its meaning to those of skill in the art. For example, the term "vector" is commonly used by those skilled in the art to refer to a vehicle that allows or facilitates the transfer of nucleic acid molecules from one environment to another or that allows or facilitates the manipulation of a nucleic acid molecule.
[0184] Any vector that allows expression of the viruses of the present disclosure may be used in accordance with the present disclosure. In certain embodiments, the disclosed viruses may be used in vitro (such as using cell-free expression systems) and / or in cultured cells grown in vitro in order to produce the encoded heterologous antigen (e.g., tumor virus antigens, HIV antigens, tumor antigens, and antibodies) which may then be used for various applications such as in the production of proteinaceous vaccines. For such applications, any vector that allows expression of the virus in vitro and / or in cultured cells may be used.
[0185] For the disclosed tumor antigens to be expressed, the protein coding sequence of the tumor antigen should be "operably linked" to regulatory or nucleic acid control sequences that direct transcription and translation of the protein. As used herein, a coding sequence and a nucleic acid control sequence or promoter are said to be "operably linked" when they are covalently linked in such a way as to place the expression or transcription and / or translation of the coding sequence under the influence or control of the nucleic acid control sequence. The "nucleic acid control sequence" may be any nucleic acid element, such as, but not limited to promoters, enhancers, IRES, introns, and other elements described herein that direct the expression of a nucleic acid sequence or coding sequence that is operably linked thereto. The term "promoter" will be used herein to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II and that when operationally linked to the protein coding sequences of the disclosure lead to the expression of the encoded protein. The expression of the transgenes of the present disclosure may be under the control of a constitutive promoter or of an inducible promoter, which initiates transcription only when exposed to some particular external stimulus, such as, without limitation, antibiotics such as tetracycline, hormones such as ecdysone, or heavy metals. The promoter may also be specific to a particular cell-type, tissue or organ. Many suitable promoters and enhancersare known in the art, and any such suitable promoter or enhancer may be used for expression of the transgenes of the disclosure. For example, suitable promoters and / or enhancers may be selected from the Eukaryotic Promoter Database (EPDB).
[0186] The vectors used in accordance with the present disclosure may contain a suitable gene regulatory region, such as a promoter or enhancer, such that the antigens of the disclosure may be expressed.
[0187] The CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) described herein may contain mutations that may prevent host to host spread, thereby rendering the virus unable to infect immunocompromised or other subjects that could face complications as a result of CMV infection. The CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) described herein may also contain mutations that result in the presentation of immunodominant and non-immunodominant epitopes as well as non- canonical MHC restriction. However, mutations in the CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) described herein do not affect the ability of the vector to reinfect a subject that has been previously infected with CMV. Such CMV mutations are described in, for example, US Patent Publications 2013-013676S; 2010-0142S23; 2014- 014103S; and PCT application publication WO 2014 / 13S209, all of which are incorporated by reference herein.
[0188] The disclosed CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) may be administered in vivo, for example where the aim is to produce an immunogenic response, including a CD8+ immune response, including an immune response characterized by a high percentage of the CD8+ T cell response being restricted by MHC- E, MHC -II, or MHC -I (or a homolog or an ortholog thereof). For example, in some examples it may be desired to use the disclosed CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) in a laboratory animal, such as rhesus macaques for preclinical testing of immunogenic compositions and vaccines. In other examples, it will be desirable to use the disclosed CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector)in human subjects, such as in clinical trials and for actual clinical use of the immunogenic compositions and vaccines.
[0189] For such in vivo applications the disclosed CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) are administered as a component of an immunogenic composition further comprising a pharmaceutically acceptable carrier. In some embodiments, the immunogenic compositions of the disclosure are useful to stimulate animmune response against the heterologous antigen, including a tumor antigen, a tumor virus antigen, or a host self-antigen and may be used as one or more components of a prophylactic or therapeutic vaccine against tumor antigens, tumor virus antigens, or host self antigens for the prevention, amelioration or treatment of cancer. The nucleic acids and vectors of the disclosure are particularly useful for providing genetic vaccines, i.e., vaccines for delivering the nucleic acids encoding the antigens of the disclosure to a subject, such as a human, such that the antigens are then expressed in the subject to elicit an immune response.
[0190] Immunization schedules (or regimens) are well known for animals (including humans) and may be readily determined for the particular subject and immunogenic composition. Hence, the immunogens may be administered one or more times to the subject. Preferably, there is a set time interval between separate administrations of the immunogenic composition. While this interval varies for every subject, typically it ranges from 10 days to several weeks, [and is often 2, 4, 6 or 8 weeks. For humans, the interval is typically from 2 to 6 weeks. In a particularly advantageous embodiment of the present disclosure, the interval is longer, advantageously about 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, 24 weeks, 26 weeks, 28 weeks, 30 weeks, 32 weeks, 34 weeks, 36 weeks, 38 weeks, 40 weeks, 42 weeks, 44 weeks, 46 weeks, 48 weeks, 50 weeks, 52 weeks, 54 weeks, 56 weeks, 58 weeks, 60 weeks, 62 weeks, 64 weeks, 66 weeks, 68 weeks or 70 weeks. The immunization regimes typically have from 1 to 6 administrations of the immunogenic composition, but may have as few as one or two or four. The methods of inducing an immune response may also include administration of an adjuvant with the immunogens. In some instances, annual, biannual or other long interval (5-10 years) booster immunization may supplement the initial immunization protocol. The present methods also include a variety of prime-boost regimens. In these methods, one or more priming immunizations are followed by one or more boosting immunizations. The actual immunogenic composition may be the same or different for each immunization and the type of immunogenic composition (e.g., containing protein or expression vector), the route, and formulation of the immunogens may also be varied. For example, if an expression vector is used for the priming and boosting steps, it may either be of the same or different type (e.g., DNA or bacterial or viral expression vector). One useful prime-boost regimen provides for two priming immunizations, four weeks apart, followed by two boosting immunizations at 4 and 8weeks after the last priming immunization. It should also be readily apparent to one of skill in the art that there are several permutations and combinations that are encompassed using the DNA, bacterial and viral expression vectors of the disclosure to provide priming and boosting regimens. CMV vectors (e.g., NHP CMV, RhCMV, or CyCMV vector) may be used repeatedly while expressing different antigens derived from different pathogens.EXAMPLESExample 1: Mapping of Viral Determinants of Species-Specific MHC-Targeting by Non-Human Primate CMVs
[0191] In several studies it was demonstrated that strain RhCMV vectors expressing SIV antigens control and ultimately eliminate infection by highly pathogenic SIVmac239. This protection was shown to correlate with the ability of RhCMV to elicit MHC-E restricted CD8+ T cells. The ability to elicit MHC-E restricted CD8+ T cells was shown to require the inactivation of Rhl57.4 and Rhl57.5, orthologs of HCMV UL128 and ULI 30, together with the inactivation of HCMV ULI 46 and ULI 47 orthologs encoded in the gene region Rhl58-161. Deletion of these genes also results in the induction of MHC- II restricted CD8+ T cells, but loss of MHC -la-restricted CD8+ T cells. Similarly, cynomolgus CMV (CyCMV) deleted for the corresponding orthologs elicited MHC-E and MHC -II restricted CD8+ T cells, but not MHC -la restricted CD8+ T cells, and protected against SIV infection. However, in contrast to the ability of RhCMV and CyCMV to elicit MHC -II and MHC-E restricted CD8+ T cells in their respective host species rhesus and cynomolgus macaques, it has been shown that RhCMV elicited MHC- la-restricted T cells when inoculated in cynomolgus and, similarly, CyCMV elicited MHC-Ia restricted T cells when inoculated into rhesus macaques.
[0192] To identify the genes responsible for the species specificity of RhCMV and CyCMV, chimeric genomes and deletion mutants were generated (FIG. 1). The chimeric vectors contained three quarter RhCMV genomes and one quarter CyCMV genome.
[0193] The RhCMV / CyCMV chimeras expressing SIV Gag antigens were inoculated into rhesus macaques (RMs) and the resulting CD8+ T cell response was determined for the entire Gag open reading frame (ORF) using 15mer peptides overlapping by 11 aminoacids. All RM elicited T cell responses to the SIV Gag ORF (FIG. 2). To specifically detect CD8+ T cells that recognized peptides in the context of MHC-E or MHC-II it wasadvantageous that supertopes within the SIV Gag protein are shared by all animals. Thus, each of the supertope peptides was tested individually by ICS in PBMC of the RM with Gag53 and Gag 73 representing MHC-II-restricted epitopes whereas Gag69 and Gagl20 representing MHC-E-restricted epitopes. Three of the four chimeras elicited responses similar to parental double-deleted RhCMV (RRRR). However, double-deleted CyCMV (CCCC) or replacement of the 3’ end quarter genome of RhCMV with that of CyCMV (RRRC) resulted in loss of MHC-II and MHC-E-restricted supertope responses. MHC-Ia restricted responses.
[0194] To determine the MHC-restriction to non-supertope peptides the RhCMV / CyCMV chimeras expressing SIV Pol or Gag antigens were inoculated into RM and MHC-restriction of the resulting CD8+ T cell response was determined at the peptide level (FIG. 3). Three of the four chimeras elicited responses to peptides that were either restricted by MHC-II or MHC-E. However, replacement of the 3’ end quarter genome with that of CyCMV (RRRC) resulted in MHC-Ia restricted responses only. In contrast, the RRRC chimeric vector was able to elicit unconventionally MHC restricted CD8+ T cells in cynomolgus macaques (FIG. 4). Thus, the 3’ end of the genome contained viral gene(s) that determined the species-specificity of T cell programming.
[0195] Additional RhCMV recombinants only carrying fragments 13, 14, 15, 16 of the CyCMV genome as well as analysis of RhCMV deletions in the 3’ end of the viral genome pointed to ORF 230 in both RhCMV (Rh230) and CyCMV (Cy230) as the likely candidate for regulating species-specific T cell priming. Although Cy230 and Rh230 are closely related, they display some differences in their predicted protein sequence (FIG.7).Example 2: Generation of Non-Human Primate CMV Vectors for Induction of MHC-E with Species Mismatched TRS1 Orthologs
[0196] To determine whether Cy230 and Rh230 are responsible for species-specific induction of MHC-E and MHC-II-restricted CD8+ T cells, RhCMV expressing Cy230 and CyCMV expressing Rh230 were generated.
[0197] RhCMV / Cy230: Starting from a complete RhCMV genome the following modifications were introduced: SIV Gag was expressed by replacing the gene Rhl3.1. The orthologs of ULI 28, ULI 30, ULI 46 and ULI 47 were deleted. The TRS1 ortholog of RhCMV, Rh230, was replaced with the TRS1 ortholog of CyCMV, Cy230. The resultingconstruct was sequence verified and the recombinant vector was reconstituted in rhesus fibroblasts. 5xl06plaque forming units (PFU) of RhCMV / Cy230 were inoculated into a RhCMV-seropositive RM (FIG. 5) or a CyCMV-seropositive MCM (FIG. 6). PBMC were isolated and the CD4+ and CD8+ T cell responses to the SIV Gag elicited were measured by intracellular cytokine staining (ICS) for ZFNy and TNFa using overlapping 15mer peptide pools that covered the SIV Gag protein. To specifically detect CD8+ T cells that recognized peptides in the context of MHC-E or MHC-II each of the SIV gag supertope peptides was tested individually by ICS in PBMC of the RM or MCM. The observed CD4+ and CD8+ T cell response to the SIV Gag peptide pool represent the total SIV Gag-specific response and demonstrate successful induction of a T cell response by this recombinant in either RM or MCM (FIGs. 5 and 6). While CD8+ T cells responding to MHC-E restricted supertopes and MHC-II restricted supertopes were not observed in RM, they were observed in MCM. Thus, replacement of Rh230 with Cy230 resulted in RhCMV losing the ability to elicit MHC-II and MHC-E restricted T cell responses in RM but acquiring the ability to elicit these responses is MCM.
[0198] CyCMV / Rh230: Starting from a complete CyCMV genome the following modifications were introduced: SIV Gag was expressed by replacing the gene Cyl3.1. The orthologs of ULI 28, ULI 30, ULI 46 and ULI 47 were deleted. The TRS1 ortholog of CyCMV, Cy230, was replaced with the TRS1 ortholog of RhCMV, Rh230. The resulting construct was sequence verified and the recombinant vector was reconstituted in rhesus fibroblasts. 5xl06plaque forming units (PFU) of CyCMV / Rh230 were inoculated into a RhCMV-seropositive RM (FIG. 5) or CyCMV-seropositive MCM (FIG. 6). PBMC were isolated and the CD4+ and CD8+ T cell responses to the SIV Gag elicited were measured by intracellular cytokine staining (ICS) for IFNy and TNFa either using overlapping 15mer peptide pools that covered the entire SIV Gag protein or to supertopes within SIV Gag (FIGs. 5 and 6). CD4+ and CD8+ T cell responses to the peptide pool were observed in RM and MCM thus demonstrating successful induction of a T cell response to the inserted antigen in both species. However replacement of Cy230 with Rh230 resulted in CyCMV acquiring the ability to elicit MHC-II and MHC-E restricted T cell responses in RMs (FIG. 5) but losing the ability to elicit these responses in MCM (FIG.6).
[0199] In contrast to non-human primate CMVs, HCMV has both terminal and internal repeat sequences. Since TRS1 is encoded in the terminal repeat sequence, there is apartially duplicated gene, termed IRS1, encoded in the internal repeat region. FIG. 8 shows an alignment between TRS1 and IRS1.
[0200] FIG. 9 shows an alignment between Rh230 and TRS1 which demonstrates that these protein sequences are related.
Claims
WHAT IS CLAIMED IS:
1. A recombinant rhesus cytomegalovirus (RhCMV) vector comprising a nucleic acid sequence encoding one or more heterologous antigens, wherein the RhCMV vector expresses an active TRS1 and / or an active IRS1 and does not express an active Rh230.
2. The recombinant RhCMV vector of claim 1, wherein the active TRS1 and / or active IRS1 are from HCMV.
3. The recombinant RhCMV vector of claim 1 or 2, wherein the recombinant RhCMV vector does not express active Rh230 due to the presence of one or more mutations in the nucleic acid sequence encoding Rh230.
4. The recombinant RhCMV vector of 3, wherein the one or more mutations in the nucleic acid sequence encoding Rh230, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the Rh230.
5. A recombinant cynomolgus cytomegalovirus (CyCMV) vector comprising a nucleic acid sequence encoding one or more heterologous antigens, wherein the CyCMV vector expresses an active TRS1 and / or an active IRS1 and does not express an active Cy230.
6. The recombinant CyCMV vector of claim 5, wherein the active TRS1 and / or active IRS1 are from HCMV.
7. The recombinant CyCMV vector of claim 5 or 6, wherein the recombinant CyCMV vector does not express active Cy230 due to the presence of one or more mutations in the nucleic acid sequence encoding Cy230.
8. The recombinant CyCMV vector of claim 7, wherein the one or more mutations in the nucleic acid sequence encoding Cy230, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the Cy230.
9. The recombinant vector of any one of claims 1-8, wherein the recombinant vector does not express an active U I 28, U I 30, ULI 46, ULI 47, or an ortholog thereof.
10. The recombinant vector of claim 9, wherein the recombinant vector does not express active ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof, due to the presence of one or more mutations in the nucleic acid sequence encoding ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof.
11. The recombinant vector of claim 10, wherein the one or more mutations in the nucleic acid sequence encoding ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof, are selected from the group consisting of point mutations, frameshift mutations, truncation mutations, and deletion of all of the nucleic acid sequence encoding the ULI 28, ULI 30, ULI 46, ULI 47, or an ortholog thereof.
12. The recombinant vector of any one of the preceding claims, wherein the recombinant vector further comprises a nucleic acid sequence encoding UL40, or an ortholog thereof.
13. The recombinant vector of any one of the preceding claims, wherein the recombinant vector further comprises a nucleic acid sequence encoding US28, or an ortholog thereof.
14. The recombinant vector of any one of the preceding claims, wherein the recombinant vector does not express active UL82 (pp71), or an ortholog thereof.
15. The recombinant vector of any one of the preceding claims, wherein the recombinant vector does not express active glycoprotein L (gL), or an ortholog thereof.
16. The recombinant vector of any one of the preceding claims, wherein the recombinant vector further comprises a nucleic acid sequence encoding a microRNA (miRNA) recognition element (MRE), wherein the MRE contains target sites for microRNAs expressed in endothelial cells.
17. The recombinant vector of claim 16, wherein the MRE is specific for the miRNA selected from the group consisting of miR126, miR-126-3p, miR-130a, miR-210, miR-221 / 222, miR-378, miR-296, and miR-328.
18. The recombinant vector of any one of claims of any one of the preceding claims, wherein the heterologous antigen is a pathogen specific antigen, a tumor antigen, a tissue specific antigen, or a host self-antigen.
19. The recombinant vector of claim 18, wherein the pathogen specific antigen is selected from the group consisting of human immunodeficiency virus (HIV), herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
20. The recombinant vector of any one of claims 1-4 and 16-19, wherein the pathogen specific antigen is an MHC-E supertope.
21. The recombinant vector of claim 20, wherein the MHC-E supertope is a HIV epitope.
22. The recombinant vector of claim 21, wherein the MHC-E supertope has a sequence having at least 80%, at least 85%, at least 90%, at least 95%, or is 100% identical to any one of SEQ ID NOs: 5-24.
23. The recombinant vector of claim 18, wherein the tumor antigen is related to a cancer selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
24. The recombinant vector of claim 18, wherein the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.
25. A method of generating an immune response in a subject to the one or more heterologous antigens, comprising administering to the subject the recombinant vector of any one ofthe preceding claims in an amount effective to elicit a CD8+ T cell response to the one or more one heterologous antigens.
26. A method of treating or preventing cancer in a subject, comprising administering the recombinant vector of any one of the preceding claims in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
27. A method of treating or preventing a pathogenic infection in a subject, comprising administering to the subject the recombinant vector of any one of the preceding claims in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
28. A method of treating an autoimmune disease or disorder in a subject, comprising administering to the subject the recombinant vector of any one of the preceding claims in an amount effective to elicit a CD8+ T cell response to the one or more heterologous antigens.
29. The method of any one of claims 25-28, wherein at least 10% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-E or an ortholog thereof.
30. The method of claim 29, wherein at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the CD8+ T cells elicited by the recombinant vector are restricted by MHC-E or an ortholog thereof.
31. The method of any one of claims 25-30, further comprising identifying a CD8+ TCR from the CD8+ T cells elicited by the recombinant vector, wherein the CD8+ TCR recognizes a MHC-E / heterologous antigen-derived peptide complex.
32. The method of claim 31, wherein the CD8+ TCR is identified by DNA or RNA sequencing.
33. The method of claim 31, wherein the CD8+ TCR recognizes MHC-E supertopes.
34. The method of claim 33, wherein the MHC-E supertope is an human immunodeficiency virus (HIV) epitope.
35. The method of claim 33 or 34, wherein the MHC-E supertope has an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the sequence of any one of SEQ ID NOs: 5-24.
36. A method of generating TCR-transgenic CD8+ T cells that recognize MHC-E-peptide complexes, the method comprising:a. administering to a first subject the recombinant vector of any one of claims 1-24 in an amount effective to generate a set of CD8+ T cells that recognize MHC- E / peptide complexes;b. identifying a first CD8+ TCR from the set of CD8+ T cells, wherein the first CD8+ TCR recognizes a MHC-E / heterologous antigen-derived peptide complex; c. isolating one or more CD8+ T cells from a second subject; and d. transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ TCR and a promoter operably linked to the nucleic acid sequence encoding the second CD8+ TCR, wherein the second CD8+ TCR comprises CDR3a and CDR3P of the first CD8+ TCR, thereby generating one or more transfected CD8+ T cells that recognize a MHC-E / heterologous antigen-derived peptide complex.
37. The method of claim 36, wherein the first CD8+ T cell recognizes MHC-E supertopes.
38. The method of claim 37, wherein the MHC-E supertopes comprise human immunodeficiency virus epitopes.
39. The method of claim 37 or 38, wherein the MHC-E supertope has an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the sequence of any one of SEQ ID NOs: 5-24.
40. The method of any one of claims 36-39, wherein the second CD8+ T cell recognizes MHC-E supertopes.
41. The method of claim 40, wherein the MHC-E supertopes comprise human immunodeficiency virus epitopes.
42. The method of claim 40 or 41, wherein the MHC-E supertope has an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to the sequence of any one of SEQ ID NOs: 5-24.
43. The method of any one of claims 36-42, wherein the first CD8+ TCR is identified by DNA or RNA sequencing.
44. The method of any one of claims 36-43, wherein the nucleic acid sequence encoding the second CD8+ TCR is identical to the nucleic acid sequence encoding the first CD8+ TCR.
45. The method of any one of claims 36-44, wherein the first subject is a human.
46. The method of any one of claims 36-45, wherein the second subject is a human.
47. The method of any one of claims 36-46, further comprising administering the transfected CD8+ T cells to the second subject to treat or prevent cancer.
48. The method of claim 47, wherein the cancer is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
49. The method of any one of claims 36-46, further comprising administering the transfected CD8+ T cells to the second subject to treat or prevent a pathogenic infection.
50. The method of claim 49, wherein the pathogenic infection is caused by a pathogen selected from the group consisting of human immunodeficiency virus, herpes simplexvirus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
51. The method of any one of claims 36-46, further comprising administering the transfected CD8+ T cells to the subject to induce an autoimmune response to the host self-antigen.
52. A method of generating CD8+ T cells that recognize MHC-E-peptide complexes, the method comprising:a. administering to a first subject the recombinant vector of any one of claims 1-24 in an amount effective to generate a set of CD8+ T cells that recognize MHC- E / peptide complexes;b. identifying a first CD8+ TCR from the set of CD8+ T cells, wherein the first CD8+ TCR recognizes a MHC-E / heterologous antigen-derived peptide complex; c. isolating one or more CD8+ T cells from a second subject; and d. transfecting the one or more CD8+ T cells with an expression vector, wherein the expression vector comprises a nucleic acid sequence encoding a second CD8+ TCR and a promoter operably linked to the nucleic acid sequence encoding the second CD8+ TCR, wherein the second CD8+ TCR comprises CDR3a and CDR3P of the first CD8+ TCR, thereby generating one or more transfected CD8+ T cells that recognize a MHC-E / heterologous antigen-derived peptide complex.
53. The method of claim 52, wherein the first CD8+ T cell recognizes MHC-E supertopes.
54. The method of any one of claims 52-53, wherein the second CD8+ T cell recognizes MHC-E supertopes.
55. The method of any one of claims 52-54, wherein the first CD8+ TCR is identified by DNA or RNA sequencing.
56. The method of any one of claims 52-55, wherein the nucleic acid sequence encoding the second CD8+ TCR is identical to the nucleic acid sequence encoding the first CD8+ TCR.
57. The method of any one of claims 52-56, wherein the first subject is a human.
58. The method of any one of claims 52-57, wherein the second subject is a human.
59. The method of claim 52-58, wherein administering the recombinant vector to the first subject comprises intravenous, intramuscular, intraperitoneal, or oral administration of the recombinant vector to the first subject.
60. The method of any one of claims 52-59, further comprising administering the transfected CD8+ T cells to the second subject to treat or prevent cancer.
61. The method of claim 60, wherein the cancer is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
62. The method of any one of claims 52-58, further comprising administering the transfected CD8+ T cells to the second subject to treat or prevent a pathogenic infection.
63. The method of claim 62, wherein the pathogenic infection is caused by a pathogen selected from the group consisting of human immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
64. The method of any one of claims 52-58, further comprising administering the transfected CD8+ T cells to the subject to induce an autoimmune response to the host self-antigen.
65. A CD8+ T cell generated by the method of claims 25-64.
66. The CD8+ T cell of claim 65, wherein the pathogen specific antigen is selected from the group consisting of human immunodeficiency virus, simian immunodeficiency virus,herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.
67. The CD8+ T cell of claim 65, wherein the tumor antigen is related to a cancer selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.
68. The CD8+ T cell of claim 65, wherein the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.
69. A method of treating or preventing a pathogenic infection in a subject, the method comprising administering the CD8+ T cell of claim 65 or 68 to the subject.
70. A method of treating or preventing cancer in a subject, the method comprising administering the CD8+ T cell of claim 65 or 68 to the subject.
71. A method of treating an autoimmune disease or disorder, the method comprising administering the CD8+ T cell of claim 65 or 68 to the subject.
72. A method of inducing an autoimmune response to a host self-antigen, the method comprising administering the CD8+ T cell of claim 65 or 68 to the subject.
